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Chapter 1. Introduction and background 
 
1.1 What is this thesis about? 
In 2004, the Norwegian Patients Rights Act was changed to offer morbidly obese persons a 
formal right to treatment within the specialist health care system1. The Ministry of Health and 
Care Services instructed the five Regional Health Authorities (RHA) to provide morbidly 
obese patients with an appropriate treatment choice: either conservative or surgical. An inter-
regional working group consisting of surgeons, administrators from the RHA’s and internists 
from the five health regions developed formal national guidelines2, which were subsequently 
revised in 20073. After consultation with Vestfold Hospital Trust, the Southern Norway RHA 
agreed to establish a project offering morbidly obese patients a complete diagnostic 
assessment and treatment. The Morbid Obesity Center (MOC) (Overvektsprosjektet i Helse 
Sør) at Vestfold Hospital Trust was thereafter established on the 1st September 2004. In June 
2005 the former Hospital for Rehabilitation, now entitled Clinic for Physical Medicine and 
Rehabilitation (CFMR) at Vestfold Hospital Trust, initiated in cooperation with MOC the 
development of the specific outpatient intensive lifestyle intervention (ILI) program discussed 
in this thesis. When initiated, this was one of the first outpatient treatment programs for 
morbidly obese patients within the Norwegian tertiary health care sector. The choice of a 
group-based ILI-program was partly based on existing evidence indicating that group-based 
treatment was a more effective treatment of morbid obesity than individual treatments4.  In 
part, the choice was also a result of practical considerations. During and after the completion 
of the studies presented and discussed in this thesis, the ILI treatment program at CFMR has 
become an established part of the non-surgical treatment at the MOC at Vestfold Hospital 
Trust. 
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In order to manage the increasing prevalence of morbid obesity5 and the accompanying 
increase in obesity related comorbidities6 there must be both effective preventive measures 
and effective treatments available for patients. The number of bariatric operations performed 
worldwide has increased dramatically during the last decade7.  Norway is no exception, with 
around 1500 bariatric operations performed in 2008 and around 3000 operations performed 
annually to date8. In addition, according to recent findings, more than one fifth of the 
population is obese (BMI≥30 kg/m2) and approximately 4-6 % has a BMI ≥35 kg/m2. 
Assuming that approximately 50 % of individuals with BMI ≥35 kg/m2 have one or more 
obesity related comorbidities, about 2-3 % of the Norwegian population may be morbidly 
obese 9. Over the last ten years more than 4000 morbidly obese patients have sought treatment 
at the MOC, representing approximately 20 % of the individuals with morbid obesity in our 
region (Former South Norway Regional Health Authority; Vestfold, Telemark, Buskerud, 
Aust-Agder, Vest-Agder) of approximately one million inhabitants. Of these treatment 
seeking patients less than half were offered bariatric surgery. The others were offered non-
surgical treatment alternatives including various individual and group-based ILI programs 
(figure 1).  
 
Figure 1. Flow chart of treatments at the Morbid Obesity Center. No permission required. 
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While the effect of bariatric surgery on various health measures was established before the 
start of this PhD-project, less was known about the effects of ILI on weight loss, 
cardiovascular risk factors and health related quality of life (HRQL). Accordingly, we decided 
to study and compare the effectiveness of newly developed intensive lifestyle intervention 
programs, on morbidly obese individuals or similar patient groups (e.g. patients with type 2-
diabetes), assuming that the results might be generalized to future treatment seeking morbidly 
obese individuals.  
The key issues in this thesis are threefold; in the first paper we compare the effectiveness of 
two public (secondary vs. tertiary care) outpatient lifestyle intervention programs in terms of 
weight loss, HRQL and physical activity. In order to compare the effectiveness of these two 
lifestyle interventions we used a non-randomized controlled pragmatic clinical design.   
In the second paper we compare the short-term effect of ILI and a low-calorie diet (LCD) in 
terms of aortic arterial stiffness (a valid surrogate marker of cardiovascular disease). Finally, 
in the third paper we compare the long-term effect of ILI on aortic arterial stiffness and 
compare this with the effect of a lifestyle intervention consisting of LCD and Roux-en-Y 
gastric bypass surgery (GBS). 
All the studies in this thesis were conducted with treatment seeking morbidly obese patients. 
The results of the first paper can be seen to provide evidence which may help to inform 
decisions regarding the design and content of lifestyle interventions in public specialist health 
care systems. The results from the second and third paper, in addition to adding to our 
understanding of the short- and long term effects of various weight loss strategies on a 
surrogate marker of cardiovascular disease, also provide evidence which can be used to 
inform decisions regarding the design and content of lifestyle interventions with or without 
bariatric surgery in public specialist health care systems.  
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 1.2 Obesity 
1.2.1 Definition of obesity 
Obesity is a medical condition in which excess body fat increases to the extent that it may 
have negative consequences for individual health10. The most common classification of the 
degree of obesity is the body mass index (BMI), defined as body weight divided by height 
squared, expressed as kg/m2 11. A high BMI brings with it an increased risk of comorbidities 
(Table 1), while the risk of several health problems also increases compared with a normal 
weight person (Table 2).  
 
Table 1. The World Health Organization’s (WHO) classification of obesity10.  
 BMI (kg/m2) Risk of comorbidities 
   
Underweight < 18.5 Low 
Normal 18.5 – 24.9 Average 
Overweight ≥ 25.0  
Preobese 25.0 – 29.9 Increased 
Obese class I 30.0 – 34.9 Moderate 
Obese class II 35.0 – 39.9 Severe 
Obese class III ≥ 40.0 Very severe 
 
A definition of the term “morbid obesity” appeared for the first time in the American Journal 
of Surgery in 1969 when Scott and Law stated: “We identify morbid obesity as existing in any 
person whose weight has reached a level two or three times his ideal weight and who has 
maintained this level of obesity for five years or more despite efforts by himself, family, 
friends and physicians to bring about effective and sustained reduction of weight to medically 
acceptable standards"12.  However, the term “ideal weight” was not specified, but assuming a 
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BMI of 20 kg/m2 as normal or ideal, a BMI of 40-60 kg/m2 might be considered to be an 
indicator of morbid obesity. Currently we use the National Institute of Health Consensus 
Development Conference Panel’s definition of morbid obesity, also referred to as clinically 
severe obesity, as either BMI ≥35 kg/m2 with at least one obesity related comorbidity or BMI 
≥40 kg/m2 13, 14.  
 
Table 2. Relative risk of health problems associated with obesity10.  
Greatly increased (relative 
risk greater than 3) 
Moderately increased 
(relative risk 2-3) 
Slightly increased (relative 
risk 1-2) 
Type 2 diabetes Coronary heart disease Cancer (breast cancer in 
postmenopausal women, 
endometrial cancer, colon 
cancer) 
Gallbladder disease Hypertension Reproductive hormone 
abnormalities 
Dyslipidaemia Osteoarthritis (knees) Polycystic ovary syndrome 
Insulin resistance Hyperuricaemia and gout Impaired fertility 
Breathlessness  Low-back pain due to obesity 
Sleep apnoea  Increased risk of anaesthesia 
complications 
  Fetal defects associated with 
maternal obesity 
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1.2.2 Obesity trends/prevalence 
Obesity is caused by either a higher energy intake or a lower energy expenditure (or a 
combination of both) than is needed for a stable weight, and is often driven by genetic 
susceptibility. Changes in the global food system, especially increasing food energy supply, 
combined with increased mechanization and motorization are major drivers of the rise in 
global obesity seen over the last 3 to 4 decades15. Parallel with increased standards of living, 
obesity as result of over-nutrition and physical inactivity has become a major threat to the 
public health worldwide16. In fact, overweight has become more of a problem than 
underweight and infectious diseases in many developed countries10. While some reports 
indicate that the prevalence of obesity has stabilized during the last decade, a recent study 
showed the prevalence of overweight and obesity to be increasing worldwide. Between 1980 
and 2013 the prevalence of overweight and obesity rose by 27.5 % for adults, and 47.1 % for 
children.  Approximately one third of the world population, (2.1 billion people) can be 
defined as either overweight or obese, with 671 million defined as obese17. There is also 
evidence that the prevalence of morbid obesity is increasing at a high rate within the obese 
population5, 18, 19. During the last decade the  prevalence of a BMI>40 kg/m2 has grown at 
twice the rate of moderate obesity, while the prevalence of a BMI>50 kg/m2 has a grown 
threefolds compared to the increase in moderate obesity5. The prevalence of obesity among 
men and women aged 40-44 years has increased in Norway over the last three to four decades 
(Figure 2). Data from Norway demonstrate an  increase in the prevalence of obesity at all ages 
and within both genders, especially among young adults9. Recent research on obesity in 
Norway demonstrates that approximately 58 % of men are overweight or obese, while 19 % 
are obese. In women the prevalence of overweight or obese is approximately 47 %, with 18 % 
obese17.  
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Figure 2. Proportion of Norwegian women and men aged 40-44 years with a BMI ≥ 30 kg/m2 
in the period 1965 to 200020.  
1.3 The burden of obesity 
The burden of disease refers to the impact of a health problem measured in terms of financial 
cost, mortality or morbidity. According to the WHO21, obesity, hyperglycemia, high blood 
pressure, tobacco usage and physical inactivity represent the five leading global risks to 
mortality.  As a country develops there is a shift from a risk of primarily infectious diseases to 
a risk of primarily non-communicable diseases (Figure 3). Further, an increase in obesity 
levels is also associated with substantial increases in treatment costs related to the many 
obesity-related diseases6. 
21 
Figure 3. The risk transition. Over time, major risks to health shift from traditional risks (e.g. 
inadequate nutrition or unsafe water and sanitation) to modern risks (e.g. overweight and 
obesity). Modern risks may take different trajectories in different countries, depending on the 
risk and the context21. 
The positive association between BMI and all-cause and cardiovascular mortality is 
documented in numerous studies22-28. Further, there are also associations between obesity and 
increased risk of coronary heart disease29, 30, metabolic syndrome31, physical inactivity32, 
cancer33, urinary incontinence34, gastro-esophageal reflux35, obstructive sleep apnea36, 
osteoarthritis37, depression38 and HRQL39. Both dietary and surgically induced weight loss 
improve the risk of cardiovascular disease in morbidly obese individuals in terms of reduced 
blood pressure, blood glucose and lipid levels40. Further, increased aerobic fitness and 
physical activity improve the risk of cardiovascular disease independent of weight loss, 
especially in unfit overweight and obese individuals41. The number of excess deaths caused 
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by obesity has been estimated at approximately 30 000 in the UK, 300 000 in the USA42, 43 
and 3.4 million worldwide44. Higher mortality rates among obese subjects seem to mainly be 
explained by obesity related comorbidities like type 2 diabetes and hypertension rather than 
by obesity alone45. Because of the increased health risk associated with obesity and the large 
increase in its prevalence, obesity has now become a major global health challenge17.  
1.3.1 Aortic arterial stiffness  
Aortic stiffness provides information on risk of cardiovascular disease beyond that provided 
by traditional risk factors46, and represents the accumulated damaging effects of these factors 
over time47, 48.  
In the early 1920’s Frank, Bramwell and Hill derived the Moens-Korteweg equation, 
illustrating that the propagation of the pulse wave along the arterial three is inversely related 
to the distensibility of the arterial tube49. When the heart contracts it generates a pulse/wave 
which moves around the circulatory system. The aortic vessels cause a cushioning-effect on 
the pulse wave and transform the periodical left ventricular ejection of blood into a 
continuous flow. This is made by the release through elastic recoil of temporary stored energy 
with every heartbeat during the systole50. The speed of this pulse wave (pulse wave velocity 
(PWV)) is related to the stiffness of the arteries49.  An increase in PWV causes a premature 
return of reflected waves in late systole with increasing central pulse pressure and thus 
systolic blood pressure. An increase in systolic blood pressure causes an increased load on the 
left ventricle with increasing myocardial oxygen demand, and is associated with left 
ventricular hypertrophy. Toto-Moukouo et al. were the first to evaluate the mechanical 
properties of large arteries in obese individuals, reporting that arterial stiffness increased 
independent of age, gender and blood pressure level51.  
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When matched for age, aortic PWV is approximately 0.5 m/s higher in obese persons than in 
non-obese persons. This difference in aortic PWV is equivalent to 5 to 10 years of aging52. 
Arterial stiffness and hypertension are closely related, with aortic stiffness and arterial pulse 
wave reflections key determinants of elevated central systolic pressure49. 
 
1.3.2 Physical inactivity 
Obesity is associated with reduced physical activity levels and increased sitting time. The 
term physical activity refers to any body movement that burns calories and includes work, 
play, daily chores and the daily commute53. Some studies find that levels of exercise, leisure 
time and physical activity have remained stable/ increased slightly over the last few  
decades54-56, albeit that these activities only represent a small part of daily physical activity. 
The main contributors to daily physical activity: activity at work, home and during 
transportation have declined due to economic growth, technological advancements and social 
changes54, 55, 57. While high levels of physical activity reduce the health risk of obesity58, 
physical inactivity is associated with increased obesity and all-cause mortality59. However, it 
is unclear if physical inactivity is a cause or a consequence of obesity. One can argue that 
obesity most likely makes it harder to engage in physical activity, while reduced physical 
activity levels can contribute to a further weight gain and thus produce a vicious circle.  
Further, there is some degree of uncertainty regarding exactly how much physical activity is 
needed to avoid weight gain60.  
 
1.3.3 Health related quality of life 
While quality of life refers to how well an individual functions in daily life and his/hers 
perceived well-being61, the most common understanding of HRQL is that it is a multi-
dimensional measurement of the impact an illness and/or its treatment has on individuals62.  
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HRQL is usually measured with either generic or disease-specific instruments. While the 
generic instruments are designed to measure HRQL across divergent populations, the disease-
specific instruments are designed to measure HRQL in a defined population. In clinical 
studies it is recommended that both types of instruments are applied63. Obesity is associated 
with impaired HRQL63-66, with improving HRQL considered to be an important treatment 
goal. While some studies have found that weight reduction is associated with improved 
HRQL67-69, a recent meta-analysis demonstrated only modest improvements in the physical 
component of HRQL, with no improvement in the mental component70.  
A recent study has demonstrated a relationship between physical activity levels and parts of 
HRQL (life satisfaction and physical function, but not mental function) in a group of severely 
obese persons prior to their undertaking a lifestyle intervention program71. Further, another 
study has demonstrated a dose dependent relationship between exercise dose and 
improvements of HRQL in obese sedentary post-menopausal women72. However, other 
studies have found that physical exercise alone does not improve HRQL, with improvement 
in HRQL occurring only when combined with a dietary intervention73. 
 
1.4 Obesity treatment strategies 
The cornerstone of obesity management is weight loss, with two concomitant principles being 
that the treatment of obesity should reduce energy intake and increase energy expenditure 
through lifelong behavioral changes. In order to achieve benefit with respect to cardiovascular 
disease (CVD) risk factors, morbidity and mortality guidelines from US and UK recommend 
a 5-10 % weight reduction 74-76,  while others, including the Norwegian guidelines, suggest 
that patients with a BMI ≥35 kg/m2 with comorbidities should achieve a greater weight loss in 
order to obtain a consistent improvement in comorbidities75, 77, 78. 
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1.4.1 Guidelines for the treatment of obesity in Norway 
According to Norwegian guidelines, obesity treatment should start at the primary care level. 
The general practitioner (GP) should, together with the patient, set realistic and relevant 
treatment objectives. Further, the GP, in coordination with dieticians and 
physiotherapists/physical educators, should offer an individualized weight loss program based 
on a healthy diet with energy restriction and an increased level of physical activity. The GP 
coordinates the treatment and decides who should be referred to an outpatient center in a 
secondary care clinic for more specialized treatment. If needed, morbidly obese patients can 
be referred from the secondary care clinic to a tertiary care center with multidisciplinary 
teams specializing in treatment of morbidly obese patients77. These tertiary care centers are 
obliged to offer either bariatric surgery or a lifestyle intervention program, both of which are 
part of, and funded by, the Norwegian public health service. The patient and the physician 
together agree upon the most appropriate choice of therapy; either surgical or conservative79. 
 
1.4.2 Physical activity 
The terms “Physical activity” and “exercise” are often used interchangeably, though clinical 
practice operates with differing definitions of the two. While the term physical activity refers 
to any body movement that burns calories, exercise is usually defined as a subcategory of 
physical activity, and refers to planned, structural and repetitive activities aimed at  improving 
physical fitness and/or health53.  
The intensity of a specific physical activity or exercise can be defined as the ratio of work 
metabolic rate to resting metabolic rate (Metabolic Equivalent of Task [MET]. One MET is 
considered the energy cost for sitting quietly, approximated for an average adult to 3.5 ml 
oxygen per kg body weight per minute or 1 kcal per kg body weight per hour80, 81 
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There is a large body of evidence suggesting that high levels of physical activity or a high 
cardio respiratory fitness reduce the health risk associated with obesity41, 58, 82-84.   
Physical activity and exercise are associated with reduction85 and maintenance86 of body 
weight, but cause only a modest weight loss without energy restriction87, 88.  
Interventions combining energy restriction and physical activity result in a larger weight loss 
than energy restriction alone, but this weight loss is in many cases only partly sustained after 
1 year89. There is a dose-response relationship between physical activity level and weight 
loss90, and vigorous physical activity seems to be more effective for weight control than slow 
walking91, 92. The effects of physical activity in preventing weight gain are modest, especially 
since adherence to a prescribed exercise program is a big challenge for obese persons84. There 
is evidence that 30 minutes moderate intensive activity daily limits the health risk of a number 
of chronic diseases, including coronary heart disease and diabetes89. The recently published 
Norwegian guidelines for physical activity suggest that adults and the elderly should perform 
physical activity with moderate intensity for at least 150 min/week, or at least 75 min/week 
with intensive physical activity. Further, it is pointed out that 300 min/week with moderate 
physical activity or 150 min/week with intensive physical activity will lead to additional 
health benefits. In addition, the general population should reduce their physical inactivity or 
sitting time to a minimum93. However, there is compelling evidence that 60-90 minutes of 
moderate or lesser amounts of vigorous activity daily is required in order to prevent weight 
regain in formerly obese individuals94.  
 
1.4.3 Behavioral change 
Traditionally, behavior intervention in obesity management has been based on the assumption 
that behaviors regulating body weight are learned, and thus can be relearned or modified95. 
Currently, researchers operate on the assumed basis that body weight is also affected by 
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factors other than behavior. These include genetic, metabolic and endocrine influences96. In 
order to promote behavioral changes a variety of techniques can be used. Behavioral 
intervention is a generic term for those approaches used to help individuals develop skills 
through which they can achieve behavioral changes96. Behavioral intervention is goal 
directed, process oriented and advocates small rather than large changes96, 97. It usually 
consists of some common components; self-monitoring, eating stimulus control, nutrition 
education, slower eating, physical activity, problem solving and cognitive restructuring95, 96.  
One often used technique to change behavior is Motivational Interviewing, which focuses on 
facilitating and engaging the latent intrinsic motivation within the client in order to change 
behavior. Further, Motivational Interviewing is a goal-oriented and client-centered counseling 
style which promotes behavior change by exploring and resolving client ambivalence98.  
 
1.4.4 Lifestyle intervention without bariatric surgery 
There are a great variety of lifestyle interventions used in the treatment of overweight and 
obesity. The cornerstone of lifestyle intervention is to increase physical activity and normalize 
eating patterns. The interventions include a variety of individual and group based treatment 
options offered by general practitioners, private institutions, local hospitals, tertiary care 
centers and various weight loss camps. The interventions are organized as out- or inpatient 
treatment with varying intensity of treatment. Key features for good long-term results include 
compliance with physical activity regimes, caloric restriction, self monitoring of weight and 
regular personal contact during the weight maintenance period99, 100. All of the above aim to 
induce a long-term weight loss of at least 5-10 %77. Lifestyle interventions combining diet and 
exercise are associated with a larger weight loss compared to diet alone87. Studies of 
overweight and obese individuals using a combination of physical activity and dietary 
interventions led to a 4-6 % weight loss after three to four years101-103, while one study reports 
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a weight loss of 6 % after approximately 10 years104. Results from studies of morbidly obese 
individuals have shown 5-20 % weight reduction after 5-24 months105-112. However, other 
long-term studies have demonstrated that two thirds of the recorded weight losses were 
regained in the follow-up period105. 
 
1.4.5 Lifestyle intervention with bariatric surgery 
Bariatric surgery has continued to evolve and develop since the 1950’s, and includes a variety 
of procedures113-115. Bariatric surgery is generally categorized as restrictive, malabsorptive or 
a combination of restrictive and malabsorptive116. Adjustable gastric banding, sleeve 
gastrectomy, and vertical banded gastroplasty are all categorized as restrictive operations116. 
Biliopancreatic diversion, jejunoileal bypass and jejunocolic bypass are categorized as 
malabsorptive procedures. Biliopancreatic diversion/duodenal switch and gastric bypass 
surgery are categorized as combinations of restriction and malabsorption116. However, there is 
also considerable evidence demonstrating that these procedures induce satiety and less hunger 
through their effect on the gut hormones116. The restrictive effect of bariatric surgery causes 
patients to feel full at an earlier period during the eating of meals. Accordingly, bariatric 
surgery may help the patients to change their eating habits, e.g. by eating smaller portions. 
Gastric bypass surgery (GBS) was developed by Mason and Ito in the 1960’s117 (Figure 4) 
and is associated with a 25 % mean long-term weight loss118. GBS accounts for almost 50 % 
of all bariatric surgery performed worldwide7, and for approximately 90 % of all bariatric 
surgery performed in Norway119.  
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Figure 4. Illustration of a Roux-en-Y gastric bypass. Illustration reproduced with permission 
from © Kari C. Toverud CMI (certified medical illustrator) from Hofsø et al.109 
 
1.5 Summary 
Obesity is one of the main medical challenges of our time. Although the cornerstone of 
treatment is reduced energy intake and increased energy expenditure, greater understanding of 
safe and effective morbid obesity treatments is needed. The number of patients undergoing 
bariatric surgery is relatively high, yet it remains unclear what long-term adverse effects there 
are120 . Further, the National Council for Priority Setting in Health Care in Norway has 
recommended that the development of high quality safe and effective conservative treatment 
programs should be prioritized121 . 
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The main aims of this thesis are firstly to compare the effectiveness of two existing morbid 
obesity lifestyle interventions in terms of weight loss, health related quality of life and 
physical activity level. Second, we compare the short term (7-weeks) effect of a low calorie 
diet and intensive lifestyle intervention on aortic arterial stiffness. Finally, we compare the 
long-term (1-year) effects of gastric bypass surgery and intensive lifestyle intervention on 
aortic arterial stiffness. 
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Chapter 2. Aims of thesis 
 
 
Paper I:  
In treatment seeking morbidly obese individuals we aimed to compare the effectiveness of an 
intensive lifestyle intervention program (tertiary care level) and a moderate lifestyle 
intervention program (secondary care level) in terms of body weight, physical activity level 
and health related quality of life. 
 
 
 
Paper II:  
We aimed to investigate and compare the 7-week effectiveness of a low calorie diet and an 
intensive lifestyle intervention program on arterial stiffness in treatment seeking morbidly 
obese individuals. 
 
 
 
Paper III:  
We aimed to investigate and compare the 59-week effectiveness of an intensive lifestyle 
intervention program and a low calorie diet followed by a Roux-en-Y gastric bypass surgery 
intervention on arterial stiffness in treatment seeking morbidly obese individuals. 
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Chapter 3. Research design and methods 
 
3.1 Trial designs 
Paper I is based on the results from a non-randomized controlled pragmatic clinical trial.  
In the original protocol (ClinicalTrials.gov identifier NCT00464984), GP’s in the county of 
Vestfold were to recruit and treat patients within the moderate lifestyle intervention (MLI) 
program. Despite several efforts, the GP who initially accepted our invitation to participate in 
the study did not recruit a sufficient number of patients. During the period from August 2006 
to November 2009 a total of 13 patients were referred to the MLI-group. Since GP’s preferred 
to refer the patients to our secondary care outpatient clinic, we found it appropriate to change 
the protocol and recruit consecutive patients from our secondary outpatient clinic to the MLI-
group. The recruitment to the MLI-group from our secondary outpatient clinic started in 
January 2010. The original study and revised protocol were approved by the regional ethics 
committee of the Southern Norway Regional Health Authority (identifier S-05175).  
Paper II and III are based on short- and long-term results from a non-randomized clinical trial, 
but we would argue that this study also had a pragmatic design according to the CONSORT 
statement122, 123. All of the interventions in this study were performed in a normal treatment 
setting at Vestfold Hospital Trust, with all patients recruited from MOC and a relatively low 
number of excluded patients. 
 
3.2 Settings, intervention overview and participants 
Settings and principles of interventions. In the study presented in paper I, patients were either 
assigned to an ILI program (at CPMR, Vestfold Hospital Trust, Stavern, Norway) or to an 
MLI program (Vestfold Hospital Trust, Larvik, Norway) (Figure 5). Patients were assigned to 
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the ILI-group between August 2006 and November 2010, while patients were assigned to the 
MLI-group between January 2010 and November 2010. 
The studies presented in paper II and III were performed at a tertiary care center (The MOC, 
Vestfold Hospital Trust, Tønsberg, Norway) between February 2008 and April 2012. In this 
non-randomised trial, patients were either assigned to ILI (at the CPMR, Vestfold Hospital 
Trust) or to a LCD followed by GBS at the MOC (Figure 6). 
 
Participants. In paper I, all participants in the ILI-group were recruited from the MOC while 
all the patients in the MLI-group were referred to our secondary care treatment center by GPs 
in the county of Vestfold. In order to be included in the study, a patient had to be considered 
morbidly obese13, 14. 
Subjects were excluded from the study if they had participated in a weight loss program 
during the previous 12 months, if they had a severe psychiatric disorder preventing 
participation in a group-based intervention, or if they were not able to walk more than 100 
meters without the use of a walking aid.  
In paper II and III, all participants were recruited from the MOC and had to reside within 100 
km from either CPMR or MOC. Patients in the ILI-group were selected from patients that had 
registered for participation in a standardized lifestyle intervention at the CPMR. Participants 
in the LCD-group, and later GBS-group, were selected from patients due to undergo bariatric 
surgery at Vestfold Hospital Trust. 
In order to be included in the study patients had to be considered morbidly obese. The 
exclusion criteria included uncompensated heart failure, cardiac arrhythmias, unstable angina, 
end-stage renal disease, known bleeding disturbances, serious psychiatric disorders, serious 
eating disorders, cardiac pacemakers, intra-cardiac devices, a cerebrovascular event or a 
myocardial infarction within the last six months. 
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Figure 5. Chart of interventions in paper I. No permission required124. 
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Figure 6. Chart of interventions in paper II & III. No permission required125. 
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3.3 Interventions (details) 
3.3.1 Intensive lifestyle intervention program 
The ILI program was conducted at “Kysthospitalet i Stavern”, which provided participants for 
all the papers discussed in this thesis. The program included both dietary energy restrictions 
and physical activities. The participants were divided into groups comprising of 12 to 14 
patients. The first year of the intervention was divided into two stages: the first 12 weeks 
included the most intensive treatment period, with treatment sessions 3 days per week for 12 
weeks. In the second part of ILI, during weeks 13-52, patients received monthly follow up, 
alternating between group based and individual sessions every other month (figure 5). During 
these group-based sessions, which lasted for 3 hours, patients performed various supervised 
water-based endurance exercises for the first hour, followed for the next 2 hours by a lifestyle 
modification intervention including nutritional and physical activity lectures (Figure 7). 
 
Dietary energy restriction 
The baseline individual energy expenditure was calculated according to Schofield’s 
equation126. Schofield’s equation uses a patient’s age, gender and body weight in order to 
calculate the basal metabolic rate (BMR). Assuming that most of the severely obese 
participants had a sedentary lifestyle127, the individual baseline energy expenditure was 
multiplied with a physical activity factor of 1.480, 81. Patients received a dietary plan with a 
reduced energy intake of 1000 kcal/day of the calculated total energy expenditure, with a 
specific aim of at least 5-10 % weight loss77.  Otherwise, the diet compiled with Norwegian 
nutritional guidelines128.  
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Time Schedule – Intensive Lifestyle Intervention – stage 1. 1-3 monthts 
 
 Monday Tuesday Thursday 
09:00 Physical activity Walking, Nordic walking Physical activity 
09:30 
10:00 Body weight and 
anthropometric measures 10:30 Education* Education* 
11:00 Education* Lunch 
11:30 Lunch Lunch 
12:00 Water activities 
12:30 Education* Education* 
13:00 
13:30 
14:00 Water activities Education* Water activities 
14:30 
15:00 End End End 
 
 
Time Schedule – Intensive Lifestyle Intervention – group sessions - stage 2. 3-12 months 
 
08:45 Body weight and anthropometric measures 
09:30 Water activities 
11:00 Education* 
12:00 End 
* Education in physical activity, nutrition and motivation. 
Figure 7. Time schedule for the first year of the intensive lifestyle intervention (No 
permission required)124. 
 
Physical activity 
During the first 12 weeks each treatment day lasted 6 hours, with patients participating in two 
supervised training sessions for 60-90 minutes (figure 7). This was followed by lectures on 
nutrition, physical activity and motivation. The first of the two supervised exercise sessions 
consisted of weight bearing activities such as walking, Nordic-walking, running, ballgames, 
resistance training and various other exercises. The second exercise session consisted of 
water-aerobics, swimming and other water-based physical activities. The main emphasis of 
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the physical training was endurance training of moderate (4 METs) to high intensity (8 
METs). The resistance training consisted of 10-15 repetitions and 2-3 sets per exercise.  
 
Behavioral change  
Group-based interventions seem to be more effective than solely individual treatments for 
obesity4. In order to invoke behavioral changes, elements of cognitive behavioral therapy129 
and motivational interviewing98 were used in both individual and group sessions. The 
program is mainly a group-based intervention, but with individual sessions in order to 
facilitate a more tailored treatment. 
The treatment team included a registered nurse, a medical doctor and physical educators with 
backgrounds in nutrition, pedagogy and adapted physical activity, the latter of which  focuses 
on the individual differences in physical activity that require special attention130. 
 
3.3.2 Moderate lifestyle intervention program  
The Moderate Lifestyle Intervention (MLI) program included outpatient treatment 1 day a 
week for 10 consecutive weeks, for 3 hours each day (figure 5). Through energy restriction 
and increased physical activity the specific treatment goal for each patient was a long-term 
weight loss of at least 5-10 %77. Each day of treatment included one session of supervised 
physical exercise such as aerobics, treadmill walking, step machines, indoor cycling and 
resistance training. The intensity of the physical endurance training was moderate (4 METs) 
to high (8 METs). Resistance training was performed with 10-15 repetitions and 2-3 sets per 
exercise. In addition, participants received lectures in nutrition, physical activity and 
motivation by the multidisciplinary team. During the first 10 weeks, patients participated in 
two water aerobic sessions. Participants were encouraged to increase their physical activity 
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levels between sessions. Participants were encouraged to attend at least 8 of 10 treatment 
sessions. 
The treatment staff in the MLI included a registered nurse, a physiotherapist, a registered 
dietician and a medical doctor.  
 
3.3.3 Low calorie diet 
The LCD consisted of a diet based on crisp bread combined with low fat products for 
breakfast, lunch and supper. Dinner consisted of fish, poultry of lean meat combined with 
potatoes, rice or pasta and vegetables. The diet provided  less than 900 kcal per day, of which 
roughly 40 % of the energy came from protein, 40 % from carbohydrates and 20 % from fat 
(estimations based on calculations from a registered dietician, Line Kristin Johnson, PhD131). 
Patients were allowed to increase the size of their meal through vegetable intake, and were 
also encouraged to drink water when eating. Daily intake of a multivitamin/mineral 
supplement was recommended. Further, participants in the LCD-group were instructed to 
maintain their level of physical activity throughout the intervention. The study participants 
were not allowed to attend other dietary or physical interventions either prior to or during the 
7 weeks of the LCD. 
 
3.3.4 Gastric bypass surgery 
The Roux-en-Y GBS was performed laparoscopically at Vestfold Hospital Trust, Tønsberg, 
Norway. The gastric pouch was about 25 ml, while the intestinal limb lengths were measured 
as follows: alimentary limb 120 cm, biliopancreatic limb 60 cm, and common limb, variable 
length. The following standardized regimen of dietary supplements was prescribed to all 
patients after surgery: 2 daily multivitamin/mineral pills, vitamin-D with calcium (10μg D3 
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and 0.5 g Ca carbonate), ferrous sulphate (100 mg to women with menstruation). Additionally 
B12 (1 mg) was given intramuscularly 1 month after surgery, then every 3 months.  
 
3.4 Outcomes 
The outcomes of primary interest in paper I were 1-year changes in body weight, HRQL and 
physical activity level. The 1-year changes in waist circumference (WC) were also analyzed. 
In paper II and III the main outcome was change in arterial stiffness measured with cfPWV. 
Secondary outcome variables were changes in body weight, body composition, systolic and 
diastolic blood pressure and pulse pressure. 
 
3.4.1 Clinical characteristics and definitions 
In all papers discussed in this thesis the anthropometric measures were conducted with 
patients wearing light clothing and no shoes. Height was measured to the nearest 0.5 cm, and 
body weight to the nearest 0.1 kg. Body mass index (BMI) was calculated as weight in 
kilograms divided by the square of the height in meters. WC was measured midway between 
the 12th rib and the iliac crest with the patient in an upright position. 
The patients in paper II and III underwent a medical examination performed by a medical 
doctor and a trained nurse. All measurements were conducted after an overnight fast. Patients 
were instructed to withdraw prescribed medications and to refrain from smoking from 24:00 
the evening prior to the examination. Blood was collected by venipuncture on the day of the 
medical examination. Resting blood pressure was measured using an electronic blood 
pressure recorder with an appropriately sized cuff (Dinamap®, ProCare Series, GE. Medical 
Systems (Buckinghamshire, UK) with the patient sitting in an upright position. Three 
measurements were recorded, and the average of the second and third recording was used in 
the blood pressure analysis. Arterial hypertension was defined by either, a systolic blood 
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pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90 mmHg or the use of antihypertensive 
medication. Mean arterial pressure (MAP) was calculated as ([diastolic blood pressure x 2] + 
systolic blood pressure)/352. Ischemic heart disease was defined as a history of stable coronary 
artery disease, percutaneous coronary intervention, coronary artery bypass graft surgery or 
myocardial infarction. Homeostasis Model Assessment Insulin Resistance (HOMA-IR) was 
calculated as ([fasting serum glucose (mmol/l) x fasting serum insulin (pmol/l)]/135132.  Low 
density lipoprotein cholesterol (LDL) concentrations were estimated by the Friedewald 
equation: LDL cholesterol = Total-cholesterol – HDL-cholesterol – (0.45 x triglycerides)133. 
S-LDL cholesterol was not calculated if S-triglycerides were <0.2 or ≥5 mmol/l. 
 
3.4.2 Health related quality of life 
In paper I, two questionnaires were used to measure HRQL: The Medical Outcome Study 12 
– item Short Form Health Survey (SF-12)134 and the Obesity and Weight-Loss Quality of life 
(OWLQOL-17)135, 136. SF-12 is a commonly used generic measure of HRQL based on 12 
questions or items from the larger 36-item Short Form Health Survey (SF-36) questionnaire. 
The items measure physical functioning, physical role limitations, bodily pain, general health, 
emotional role limitations, general health, emotional role limitations, vitality, social 
functioning and mental health. The items were scored in accordance with the 
recommendations from the scale author134 and then combined into two summary scores; the 
physical HRQL and the mental HRQL. The OWLQOL-17135, 136 is primarily a measure of the 
emotions and feelings137, 138, which are believed to result from being obese and trying to lose 
weight. The instrument consists of 17 statements about weight-related feelings and emotions 
rated on a seven-point scale that ranges from 0 (“not at all”) to 6 (“a very great deal”). The 17 
items of the OWLOQOL form a scale ranging from 0 to 102, with higher scores indicating a 
better emotional HRQL. 
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3.4.3 Physical activity 
In paper I, physical activity levels was investigated using a 7-day recall questionnaire 
validated against accelerometer in time spent engaged in physical activity of varying intensity 
in a normal weight population139. The questionnaire divides the day into five main parts: 
work, transport, domestic work, leisure time and sedentary activity, reporting time spent in 
physical activity in each of these parts. Physical activities were graded according to intensity 
by Ainsworth et al81, and time spent in physical activity ≥3 METs and ≥5 METs during the 
whole week were summed.  
In Paper III, physical activity level was measured with a self-reported questionnaire 
(CONOR)140 at 59 week follow-up and self-reported time spent in physical activity during an 
average week during the last year was registered. The CONOR questionnaire divides physical 
activity into two main parts: leisure time physical activity and occupational physical activity. 
Physical activity during leisure time was further divided into light physical activity (not 
sweaty and breathless) and vigorous physical activity (sweaty and breathless), and was scored 
according to type of work (mainly sedentary, mainly walking, mainly walking and carrying, 
heavy manual labor)140.  
 
3.4.4 Carotid to femoral (aortic) pulse wave velocity 
There are a number of different methods used in order to assess aortic arterial stiffness49, but 
cfPWV has emerged as the “gold standard” method because of its ease of use and its perceived 
reliability, and because of the large body of evidence across various populations 
demonstrating its association with cardiovascular disease independent of traditional risk 
factors47, 48, 141-152. The Sphygmocor system (Atcor, Sidney, Australia) and a single high-
fidelity applanation tonometer (Millar®) were used to measure cfPWV in paper II and III. 
Pulse waves were obtained sequentially from the carotid and femoral artery. The locations of 
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the sternal notch, carotid pulse and femoral pulse were located. The travel distance was 
calculated by subtracting the distance between the carotid artery and the sternal notch from 
the distance between the sternal notch and the femoral artery49. The subtracted travel distance 
measured at baseline was used in the calculations of cfPWV at follow-up. 
With patients lying in a horizontal position the cfPWV was calculated from the transit time 
and the distance between carotid- and femoral artery sites, determined in relation to the R-
wave of the ECG. Blood pressure was measured before every recording and entered into the 
Sphygmocor recorder in order to secure a valid recording with similar blood pressure. Three 
complete sets of data were collected and the average value was used as result. 
 
3.4.5 Bioelectrical impedance analysis 
The InBody 720 Body composition analyzer, Biospace Co. Ltd (Seol, South Korea) was used 
to measure body composition in paper II and III. The InBody 720 uses a multi-frequency 
electrical current at 5, 50, 250, 500 and 1000 kilohertz in order to measure the amount of 
extracellular and intracellular water. The InBody 720 uses segmental bioelectrical impedance 
analysis (BIA) in order to examine the body as five cylinders (four limbs and trunk), and 
measures impedance in these parts separately. Lean body mass consists of 73.3 % water, 
regardless of race or gender153. When the volume of total body water is known then the lean 
body mass can be calculated. The amount of fat mass is obtained by subtracting the calculated 
lean body mass from total weight. The InBody 720 provides data on skeletal muscle mass, 
visceral fat area, fat mass and fat free mass. To avoid measurement error, measurements were 
conducted with patients in their underwear and positioned in an upright position on the body 
composition analyzer. All jewelry and wristwatches were removed before measurement. 
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3.4.6 Laboratory analysis 
In paper II and III analyses of serum glucose and blood lipids were performed using dry 
reagent slide technology on the Vitros FS 5.1 (Ortho-Clinical Diagnostics, New York, USA). 
Glycated hemoglobin (HbA1c) was analyzed using high performance liquid chromatography 
on Tosoh HLC-723 G7 (Tosoh Corporation, Tokyo, Japan). Sera for analysis of insulin were 
stored at -20 °C and analyzed within one week of blood sampling (Linco Research Inc, St. 
Charles, MO). 
 
3.5 Sample size 
The sample size in paper I was calculated based on an estimated mean (standard deviation 
[SD]) weight loss of 4 (9) % in the MLI group and 10 (9) % in the ILI group. In order to 
achieve an 85 % power (α=0.01) at least 120 individuals had to complete the study (60 in each 
group). The α-value gives the probability of rejection of a null hypothesis that is actually true 
(type I error). To allow for a dropout rate of 40 %, we initially opted to include at least 200 
patients (100 in each group).  
The sample size in paper II and III was calculated based on Barinas-Mitchell et al’s study154 
which showed that a mean weight reduction of 8 % resulted in 1.4 m/s mean reduction in 
cfPWV in overweight patients with type 2 diabetes. From this, we hypothesized that the mean 
cfPWV would be 8.2 m/s in both groups at baseline, and that a 1-year weight loss of 8 % in the 
ILI-group would lead to a mean (SD) of 1.4 (2.8) m/s reduction in cfPWV. The expected 
weight loss following GBS is roughly 3 times as high, and we assumed that the mean 
reduction in cfPWV would be 2.8 m/s. Accordingly, at least 120 individuals had to complete 
the study in order to show a statistically significant difference between the two groups at a 
power of 80 % (α=0.05), To allow for a drop-out rate of <40 %, we decided to include 200 
patients within the study (100 in each group). 
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3.6 Statistical methods 
Data are presented as mean (SD) or number (%) unless otherwise specified. Differences 
between groups at baseline were analyzed using independent samples t-tests for continuous 
data and Fisher’s exact tests for categorical data. Unadjusted between groups differences were 
analyzed using independent samples t-test for continuous data and Fischer’s exact test for 
categorical data. Within-groups changes from baseline to follow up were analyzed using 
paired samples t-tests for continuous data and McNemar’s test for paired proportions. 
In paper I, we aimed to compare the effectiveness of an ILI and MLI in terms of changes in 
body weight, time spent in physical activity >3METS, time spent in physical activity 
>5METS, and physical-, mental- and emotional dimensions of HRQL as effect variables 
(dependents). The differences between groups were analyzed using analysis of covariance 
(ANCOVA) and include age, gender and the baseline value of the dependent variable as 
covariates155. The main aim of the study in Paper I was to analyze the overall effect of the two 
treatment programs, and we thus performed an intention-to-treat analysis using ANCOVA 
with missing data imputed using multiple imputation (MI)156. MI involves three distinct steps. 
First, plausible values for the missing data are filled in M times to generate M complete 
datasets. Second, the M complete datasets are analyzed using standard statistical methods. 
Thirdly, the results from the M analyses are combined. Missing values at 1 year (weight, WC: 
26 %, SF-36:47 %, physical activity >3 and 5 METS: 48 % and OWLQOL: 49 %) were 
imputed. The MI model consisted of the following predictor variables: treatment group, 
gender, age, baseline and 3 months weight and WC; while 1 year weight, WC and all physical 
activity measures and HRQL scores were used as both predictor and imputation variables. 
Through a fully conditional specification, applying linear regression as prediction method, we 
generated M = 5 complete imputed datasets with 10 iterations per dataset. One year BMI (26 
% missing) was calculated on the basis of measured height and the imputed weight variable.  
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In order to test for  clinically significant differences we calculated the effect size (ES) of the 
changes in HRQL157. Within-group ES was calculated as the mean HRQL change score 
between 1 year and baseline divided by the SD of HRQL at baseline in the respective group. 
Between-group ES was calculated as the difference in mean HRQL change score between 
groups at 1 year divided by the SD of  baseline HRQL in both groups combined157, 158. ES 
<0.50 was considered small, between 0.50 to 0.79 as moderate and ES ≥ 0.80 as large159. 
In paper II, we aimed to compare the effectiveness of an ILI and a LCD (paper II), while in 
paper III we aimed to compare the effectiveness of an ILI and a LCD followed by a Roux-en-
Y gastric bypass surgery. Both studies were performed with change in cfPWV as the main 
effect variable (dependent).  
The between-group differences in cfPWV at follow up were assessed using ANCOVA and 
include age, gender, baseline BMI, baseline MAP, history of coronary artery disease and 
baseline value of cfPWV as covariates. The results are presented as mean (95%CI)155. 
 
3.7 Ethics, approvals and founding 
All the study protocols (including revisions and amendments) in this thesis were approved by 
the regional ethics committee of the southern Norway Regional Health Authority (S-05715) 
(amendment to the original protocol “Overvektsprosjektet (OVP) i Helse Sør”). The studies 
were performed according to the principles expressed in the Declaration of Helsinki160, with 
written informed consent provided by all participants.  
The study presented in paper I is registered in the ClinicalTrials.gov-registry with identifier 
NCT00464984. 
The studies presented in paper II and III are registered in the ClinicalTrials.gov-registry with 
identifier NCT00626964. 
This work has been funded in its entirety by Vestfold Hospital Trust. 
  
47 
Chapter 4. Results 
 
4.1 Paper I 
Patients who accepted the invitation to participate and who satisfied the inclusion criteria 
were recruited consecutively from both centers to the ILI-group and MLI-group. The number 
of patients who declined to participate is unknown. A total of 372 patients were included, 232 
(65 % female) in the ILI-group, and 140 (75 % female) in the MLI-group (Figure 8). There 
were no significant differences between groups in terms of age, body weight or physical 
activity level. However, the ILI-group had a lower proportion of women and higher mean 
(SD) scores in the mental dimension (48.0 (11.1) vs. 44.6 (11.8) and emotional dimension 
42.9 (20.4) vs. 36.1 (20.0) of HRQL, all p<0.04. 
Of the included patients in the ILI-group, a total of 225 (97 %) completed the first 12 weeks 
of the intervention and 181 (78 %) attended the 1-year follow up. In the MLI-group a total of 
131 (94 %) completed the intervention, but only 61 (44 %) attended the 1-year follow up 
(Figure 8). Completers in the ILI- and MLI-groups had an adherence rate of 86 % (39 of 46 
sessions) and 87 % (13 of 15 sessions) respectively. 
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Figure 8. Flow chart of participants in paper I. No permission required124. 
 
The mean (95%CI) 1-year body weight reduction was significantly larger in the ILI group -10 
% (-11, -9) compared to the MLI group -2 % (-6, -1), p<0.001 (figure 9). 
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Figure 9. Mean body weight change (percent, 95%CI) after 3 and 12 months of intensive 
lifestyle intervention (ILI) or moderate lifestyle intervention (MLI). Differences between 
groups at 1 year were assessed by ANCOVA, with age, gender and body weight at baseline as 
covariates. 
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Figure 10. Percentage of all included patients who achieved weight loss ≥5 % , ≥10 %, and 
≥20 % after one year intensive lifestyle intervention (ILI) n=225) or moderate lifestyle 
intervention (MLI) (n=73). Between-group changes were analysed with Fisher’s exact test. 
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Further, the proportions of patients achieving ≥5 %, ≥10 % or ≥20 % weight loss were 
significantly higher in the ILI-group (figure 10). 
 
There was no significant change in either levels of light- or moderate physical activity 
between patients in the ILI- or MLI group. Only patients in the ILI-group had a significantly 
increased level of light intensity physical activity (>3METs) of 29 (15 to 46) min and level of 
moderate intensity physical activity (>5METs) of 29 (21 to 39) at one year follow-up, both 
p<0.001. 
 
Patients in the ILI-group had significantly larger improvements in all dimensions of HRQL 
compared to patients in the MLI-group, and this was particularly pronounced in the emotional 
dimension with a between-group difference (95%CI) of 17.8 (12.8 to 22.6) points, p<0.001, 
ES 0.77. Between-group differences in the physical dimension were 6.9 (4.4 to 9.3) points, 
p<0.001, ES 0.54; and mental dimension 4.4 (1.4 to 7.4) points, p=0.018, ES 0.18. 
 
4.2 Paper II & III  
A total of 200 patients were included in the study (64 % female), 102 in the ILI-group and 98 
in the LCD-group (Figure 11). The groups did not differ significantly in terms of cfPWV, but 
patients in the LCD-group were slightly younger and had higher systolic blood pressure and 
pulse pressure, higher body weight and fat mass, and lower prevalence of ischemic heart 
disease compared to patients in the ILI-group. During the first 7 weeks, 14 individuals in the 
ILI-group and 7 individuals in the GBS-group withdrew or did not attend the 7 week follow 
up.  
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Figure 11. Flow chart of participants in paper II & III. No permission required125. 
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4.2.1 Paper II 
After 7-weeks (paper II) the ILI-group had a larger reduction in cfPWV compared to the LCD-
group, with an adjusted between-group mean difference (95%CI) of 0.4 (0.1 to 0.6) m/s 
(figure 12). Further adjustment for weight loss and change in MAP slightly attenuated the 
difference between groups, but it remained significant [0.3 (0.1 to 0.6) m/s, p=0.019]. Only 
the ILI–group had a significant reduction in mean cfPWV, while the reduction in the LCD-
group was not statistically significant. 
 
Figure 12. Changes in cfPWV after 7 weeks of follow-up. Within groups (a), adjusted 
difference between groups (b). 
 
Both treatment groups demonstrated significant weight reductions, reduction in fat mass and 
skeletal muscle mass (all p≤0.001), but adjusted analysis showed a significantly larger weight 
loss and reduction in skeletal muscle mass in the LCD-group; between groups difference of 
1.5 (0.5 to 2.6) kg, p=0.006 and 0.8 (0.5 to 1.1) kg, p<0.001. No significant differences were 
apparent in terms of fat mass. Spearman’s rank correlation analysis demonstrated no 
significant associations between change in cfPWV and weight loss (r=-0.02, p=0.821), loss of 
skeletal muscle mass (-0.06, p=0.397) or loss of fat mass (r=0.04, p=0.590). 
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4.2.2 Paper III 
During the final period of 52 weeks an additional 13 patients in the ILI-group and 9 patients 
in the GBS-group withdrew, while one patient reentered the ILI-group at 59 weeks follow-up. 
This leaves 159 (64 % female) completers (80 % of all included patients) in the present 
analysis, a total number of 77 (76 %) and 82 (84 %) in the ILI-group and GBS-group, 
respectively (figure 11).  
The adjusted analysis showed no significant differences in change of cfPWV between 
treatments groups 0.05 (-0.4 to 0.5) m/s, p=0.831. Aortic cfPWV did not change significantly 
from baseline to 59-weeks in either the ILI- or the GBS-group (figure 13). 
 . 
Figure 13. Short- and long-term mean adjusted changes in aortic carotid femoral pulse wave 
velocity (cfPWV) (m/s, 95%CI) in the morbidly obese patients who underwent intensive 
lifestyle intervention (ILI) or Roux-en-Y gastric bypass surgery (GBS). 
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Figure 14. Scatterplots of the relationship between changes in the explanatory variables body 
weight, BMI and waist circumference, and changes in the effect variable cfPWV within each 
treatment group. 
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Reduction in body weight, BMI and waist circumference were associated with decreasing 
cfPWV in the ILI-group, but with increasing cfPWV in the GBS-group (figure 14). After 
adjustments for age, gender, history of coronary artery disease, and baseline values of BMI, 
MAP, heart rate and cfPWV, multiple linear regression analysis showed that the associations 
between changes in cfPWV and changes in WC, BMI and body weight remained statistically 
significant in the GBS-group only (all p<0.006). 
There was a significantly larger reduction in heart rate in the GBS-group compared to the ILI-
group, with a between-group difference of 7 (3 to 10) beats/min, p<0.001. Both the ILI- and 
GBS-group had a significant reduction in heart rate of -6 (-8 to -3) beats/min, p<0.001, and -
11 (-14 to -9) beats/min, p<0.001, respectively.  
There were significant reductions in the proportion of patients treated with anti-hypertensive 
and anti-diabetic drugs in the GBS-group only. Specifically, the number of patients treated 
with Renin-angiotensin-aldosterone-system (RAAS) -inhibitors, beta blockers and diuretics 
decreased from 23 to 13 (44 %), 10 to 4 (60 %), and 15 to 7 (53 %), all p< 0.031.The use of 
sulfonylurea and metformin decreased from 8 to 0 (100 %) and 16 to 3 (81 %), p=0.008 and 
p<0.001. There was no significant change in the use of statins in either group, both p≥0.375.  
The majority of patients reported that they completed >3 hours/week of light physical activity 
and >3 hours/week of vigorous physical activity at follow up, with no significant difference 
between groups (Table 3). 
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Table 3. Self-reported physical activity at 59 weeks follow up in morbidly obese patients who 
completed the interventions. 
  Intensive lifestyle 
intervention 
(n=60) 
Gastric bypass 
surgery 
(n=54) 
P-value 
Light physical 
activity 
Nothing 0 (0) 0 (0) 0.880 
≤1 hour/week 1 (2) 1 (2) 
1-2 hours/week 7 (12) 8 (15) 
≥3 hours/week 52 (87) 45 (83) 
Vigorous 
physical activity 
Nothing 2 (3) 6 (11) 0.267 
≤1 hour/week 5 (8) 7 (13) 
1-2 hours/week 21 (34) 17 (32) 
≥3 hours/week 34 (55) 24 (44) 
Work Sedentary work 23 (39) 19 (36) 0.485 
Walking 24 (41) 19 (36) 
Walking and 
carrying 
11 (19) 11 (21) 
Heavy manual 
labor 
1 (2) 4 (8) 
Number (%), between group differences analyzed using Chi-Square test. The response rate of self reported physical activity 
level was 78 % in the ILI-group and 66 % in the GBS group. 
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Chapter 5. Discussion 
 
The main results of the papers included in this thesis are:  
Paper I) A 1-year intensive lifestyle intervention program at a public tertiary care centre was 
significantly more effective than a 1-year moderate lifestyle intervention program at a 
secondary care centre at producing weight loss and improving health related quality of life.  
 
Paper II) Patients who underwent a comprehensive 7-week ILI program had a significantly 
larger reduction in aortic stiffness than those who completed a 7-week low calorie diet 
intervention. 
 
Paper III) There were no significant differences between treatment groups and no changes in 
aortic stiffness after either intensive lifestyle intervention or Roux-en-Y gastric bypass 
surgery after 59 weeks, despite considerable weight loss in both groups. 
 
The main limitations and strengths of the studies are summarized in Table 4 and discussed 
separately below. 
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Table 4. Study design and the main limitations and strengths of papers I, II, and III. 
Paper Design Limitations Strengths 
Paper 
I 
Non-
randomized 
controlled 
pragmatic 
clinical trial 
x Reduced internal validity due to 
allocation bias (lack of 
randomization) and high attrition 
rate 
x Lack of data describing adherence 
x Self-reported level of physical 
activity 
x External validity: Results are 
generalizable to similar 
populations.  May reflect the 
complexity and diversity of 
everyday clinical practice. 
x The use of supervised physical 
activity 
Paper 
II & 
III 
Non-
randomised 
controlled 
pragmatic 
clinical trial 
x Reduced internal validity due to 
allocation bias (lack of 
randomization) (paper II & III) 
x Lack of data describing adherence 
(paper II & III) 
x Self-reported use of medications 
(paper II & III) 
x Self-reported use of medications 
and level of physical activity 
(paper III) 
 
x Relatively large sample size 
(paper II & III) 
x The use of a gold standard 
method when assessing cfPWV 
(paper II & III) 
x Few drop-outs (paper II & III) 
x All measurements were 
conducted at one center by two 
trained operators (EG and NN), 
both present at all measurements 
(paper II & III) 
 
5.1 Methodological considerations 
 
5.1.1 Study design, generalizability and statistics 
 
Study design 
In order to show the efficacy of various health care interventions it is recommended that 
randomized controlled trials are used161.  Accordingly, it might be reasonable to question why 
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the studies discussed in this thesis all have a non-randomised design. Although randomised 
trials often are preferable, randomisation is not always practicable or even desirable162. 
Weaknesses with a RCT-design could be several exclusion criteria, selection bias and low 
external validity, all with subsequent low generalisability163, 164. In cases where there are good 
arguments against randomisation, useful clinical knowledge can be obtained through well-
designed non-randomized studies165. Since all treatments discussed in this thesis were 
publicly funded, patients were encouraged to take an active role in their choice of treatment 79. 
We thus found it most appropriate to use a pragmatic non-randomized comparative study 
design. However, non-randomized trials are associated with lower internal validity and 
introduce elements of allocation and selection bias166.   Patients included in the ILI-group in 
paper I were, for example, recruited from our tertiary health care center, while patients in the 
MLI-group were recruited from a local secondary care hospital, both of which treat only 
morbidly obese individuals. This referral of patients from different populations and locations 
introduced elements of selection bias. In addition, data on the number and characteristics of 
the patients who declined to participate in the study are missing. Treatment seeking morbidly 
obese patients in the southern part of Norway (Health Region South-East = Helse Sør-Øst) are 
primarily referred to secondary health care clinics from general practice, and, if needed, from 
secondary health care institutions to tertiary health care centers. Accordingly, patients 
recruited from tertiary health care centers probably have more severe forms of obesity and 
comorbidities than patients referred from secondary health care. Further, patients recruited 
from our tertiary health care center were probably more motivated for lifestyle intervention 
treatment, while the population referred from general practice consisted of both individuals 
motivated for lifestyle intervention and bariatric surgery.  In addition, the ILI was more 
intensive and required greater absence from work and family compared to the MLI. This 
could have resulted in a higher proportion of highly motivated patients among patients in the 
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ILI-group. This could also partly explain the difference in attrition rates between the two 
groups.  
 
However, the main aim in the study presented in paper I was to compare the effectiveness of 
two outpatient lifestyle interventions offered treatment seeking morbidly obese individuals in 
southern Norway. While efficacy is used to assess if a treatment works, effectiveness relates 
to how well a treatment works in real life (normal clinical practice) 123. Pragmatic trials are 
designed to better reflect the complexity and diversity of everyday clinical practice167, and 
makes it possible to compare and assess the effectiveness of two interventions relevant to 
real-life clinical care123, 166. The results presented in Paper I may therefore contribute to the 
body of evidence from which decisions about the design and distribution of lifestyle 
interventions are based upon. The local obesity center has, as a consequence of this study, 
implemented changes in the MLI program to improve its effectiveness on various outcomes.  
The studies presented in paper II and III compared the effectiveness of two established 
treatment methods (lifestyle intervention with- or without surgery) on aortic arterial stiffness. 
However, these studies also have characteristics comparable with an efficacy trial design122, 
123.  
We found it unethical to operate on individuals who both qualified for and preferred 
conservative treatment.  As patients largely chose their treatment type themselves, this 
probably caused a selection of patients to the different treatments, e.g in terms of motivation 
for treatment (allocation bias). This thus limits the internal validity of the studies. In addition, 
the high attrition rate could cause attrition bias in all three studies, where this is most 
pronounced in paper I. It is plausible that patients who achieved a satisfactory weight loss or 
maintenance were more likely to attend follow up, while patients who did not achieve a 
satisfactory weight loss were more likely to drop out. This could be associated with larger 
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differences in weight loss, and changes associated with weight loss (body composition, 
HRQL, physical activity level and aortic arterial stiffness) between treatment groups.  
 
Generalisability (external validity) 
All studies discussed in this thesis were performed in treatment seeking morbidly obese 
patients (from the southern part of Norway) who underwent various treatment programs 
offered by secondary and tertiary public health care centers. Accordingly, the results may be 
generalized to similar populations.  However, the results may not be generalized to the 
general non-treatment seeking class II and III obese population which may differ from the 
participants in our studies with respect to comorbidities, socio-economics and other unknown 
factors. It is likely that the prevalence of obesity related comorbidities among patients with 
BMI between 35 and 40 kg/m2 (class II) is higher in the sample population compared to the 
general class II obesity population. Further, in all three papers the included patients had to 
reside within 100 km from MOC or CPMR. During the period of patient inclusion in papers II 
and III, approximately 1500 patients were referred to and treated at MOC. In addition, the 
cohorts investigated in the papers consisted of mainly white Caucasians. This may limit the 
external validity of our results. 
 
Statistics 
We report two-tailed p-values and considered values below 0.05 to be significant. As the 
number of independent variables tested for significance in relation to an outcome increases, 
the risk of a significant result by chance increases (type 1 error – the incorrect rejection of a 
true null hypothesis)168. Since several statistical analyses were performed throughout the 
papers in this thesis, we cannot exclude the possibility that multiple comparisons might have 
biased our results, and particular attention should be directed towards results with small p-
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values e.g. p<0.01. One example of a p-value which should be interpreted with caution is the 
significant reduction in the emotional dimensions of HRQL in the MLI-group after 
adjustments (p=0.032). Although significant, one can ask if this represent a true effect in the 
MLI-group, since there was no significant reduction in either the mental or the physical 
dimension of HRQL. 
In the study presented in paper I the main aim was to analyze the overall effect of the two 
treatment programs, not merely of completers, and we thus performed an intention-to-treat 
analysis using ANCOVA with missing data imputed using multiple imputation (MI)156. In MI 
the missing values are predicted using existing values from other variables. Standard 
statistical analyses were carried out on each imputed data set, producing multiple analyses 
results. These analyses results were then combined to produce one overall (pooled) result169, 
170. The missing values accounted for in Paper I may produce a risk of biased estimates, 
however the usage of multiple imputation most likely reduced this risk170. In paper I, a paired 
sample t-test showed that patients in the MLI-group did not experience significant weight loss 
after 1 year. On the other hand, after adjustments, according to the 95% CI the 1 year weight 
loss in both groups were statistically significant.  
The clinical relevance of changes in HRQL was assessed by the calculation of effect size 
(ES)157, 158. An ES ranging from 0.2 to 0.49 was considered small, an ES from 0.5 to 0.79 was 
considered moderate, and an ES greater than 0.8 was considered large159. Even if there are 
statistical within- or between group differences, the differences do not need to be clinically 
relevant. In paper I there were statistical significant differences between ILI and MLI in both 
the physical- (p<0.001), mental- (p=0.018) and emotional dimension of HRQL (p<0.001). 
However, the clinical relevance of these differences are considered low (mental HRQL 
ES=18) to moderate (physical HRQL ES=0.54, emotional HRQL ES=0.77). 
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5.1.2 Hypothesis testing, limitations and validity of questionnaires 
 
Paper I 
Hypothesis testing 
The main hypothesis in paper I that “an ILI program (tertiary care level) would have a greater 
effectiveness than a MLI programme (secondary care level)” was confirmed in terms of 
weight loss and HRQL, but not in terms of physical activity level.  
 
Assessment of physical activity – self report questionnaire 
Physical activity level was measured using a 7-d recall questionnaire validated against 
accelerometer in time spent engaged in physical activity of varying intensity in a normal 
weight population139. This questionnaire divides the day into five main parts: work, transport, 
domestic work, leisure time and sedentary activity. Physical activities were graded according 
to intensity80, 81, and time spent in physical activity >3METs and >5Mets during the whole 
week were summed, and average time per day spent in physical activity >3METs and 
>5METs were calculated. The value of this questionnaire in general, and especially in a 
morbidly obese population, is questionable. Self-reported physical activity measured with this 
questionnaire correlated moderately with physical activity measured with accelerometer in 
physical activities with intensities <3METs (r=0.47) and 3-6METs (r=0.38), while there was a 
weak correlation measuring physical activities with intensity >6METs r=0.18)139. The 
questionnaire seems to underreport the amount of time spent in physical activity with intensity 
>3METs and overreport the amount of time spent in physical activity with intensity ranging 
from 3-6 METs. However, this validation is performed in a normal-weight population. 
Further, there are several limitations and uncertainties associated with the use of self reported 
measurements of physical activity level in general, and obese individuals seem too 
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considerably underreport energy intake and overreport the amount of physical activity 
undertaken171. On the other hand, we experienced that change in physical fitness could affect 
how patients assessed both the intensity and amount of physical activity undertaken. 
Individuals with higher degrees of physical fitness would most likely assess activities as less 
vigorous compared to less physically fit individuals. Patients in the ILI-group conducted a 
physical performance test on a motorized treadmill and demonstrated a significant increase in 
physical fitness from baseline (data not shown). This increase in physical fitness could thus 
cause an underreporting of their physical activity level. On the other hand, physically fit 
individuals might be more aware their physical activity level, which might lead to an 
overreporting of the amount of physical activity undertaken. The limitations and uncertainty 
associated with the use of this questionnaire to assess physical activity level weaken the 
validity of the data, and as a consequence interpretation of these data should be undertaken 
with caution.  
 
Assessment of Health Related Quality of Life – generic and disease specific questionnaires 
We used two questionnaires to measure HRQL: the Medical Outcome Study 12 – Item Short 
Form Health Survey (SF-12)134 and the Obesity and Weight-Loss Quality of Life 
(OWLQOL)135, 136. The SF-36 is validated in patients with morbid obesity, and the two 
summary scales of the SF-36 demonstrate a satisfactory validity in morbidly obese patients172. 
Further, the results from SF-12 and SF-36 correlate strongly in obese and non-obese 
patients173. The OWLQOL has been validated in obese and morbidly obese individuals. The 
studies concluded that the instrument was, valid, reproducible and responsive in terms of the 
measurement of self-reported outcomes in obesity136. However, one limitation is that we did 
not include measurement of weight-related symptoms135, which might be of importance when 
comparing interventions with differences in amount-, type and intensity of activities. Due to 
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this we were only able to investigate the mental, physical and emotional dimensions of 
HRQL.  
 
Paper II and III 
Hypothesis testing 
The main hypothesis in paper II; that a seven-week ILI program consisting of aerobic 
endurance training 3 days a week and a moderate daily calorie restriction would have a 
greater effect on arterial stiffness than a seven-week LCD: was confirmed.  
In contrast, the main hypothesis in paper III: that patients who underwent Roux-en-Y gastric 
bypass surgery after an initial low calorie diet would have a larger mean 1-year reduction of 
cfPWV compared to those who underwent an intensive intervention program: was not 
confirmed.  
 
Assessment of aortic pulse wave velocity (cfPWV) 
To measure cfPWV we used the Sphygmocor system (Artcor, Sidney, Australia) and a single 
high-fidelity applanation tonometer (Millar®). The measurement of aortic arterial stiffness by 
cfPWV is considered to be the gold standard method49, 146. Inaccuracies regarding 
measurements of distance could influence the absolute value of cfPWV and infer validity 
problems174. In order to overcome this problem we placed the tape directly above the points of 
measurement with patients laying down, which in turn enabled us to get a valid measure of 
the carotid-to-femoral distance49. Due to bulging body parts in morbidly obese individuals, we 
cannot exclude that an error was introduced when the distances were measured. However, this 
possible bias has most likely not affected the results in Papers II and III given that carotid to 
femoral distance was measured only at baseline, and the only change between baseline and 
follow up was the time for the pulse wave to travel the distance measured at baseline175. 
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Weight loss and bioimpedance analysis 
Body composition was measured using bioimpedance analysis (BIA). BIA is not a gold 
standard method: it under predicts percentage body fat by a mean of 5.7 % in men and 9.1 % 
in women when compared with the hydrostatic weighing method176.  The Inbody 720 used in 
papers II and III has not been validated against hydrostatic weighing, but it has been validated 
against Dual x-ray absorptiometry (DEXA) in obese patients, and has been shown to under 
predict percentage body fat in obese men by 5 % and by 6 % in women177. Further, the 
assumption of constant tissue hydration essential for BIA could be violated after weight loss. 
However, results from a study investigating the effect of one month of energy restriction in 48 
obese subjects (mean weight loss 8.6 kg) showed no vector displacement, indicating that 
liquid homeostasis was maintained after the weight loss178.  
 
Assessment of physical activity-the CONOR questionnaire 
To measure physical activity level in Paper III we used the CONOR (Cohort of Norway) 
questionnaire140. The questions used in the CONOR questionnaire have been validated against 
accelerometer and VO2max in normal weight men aged 20-39 years. There was a moderate 
agreement for hard leisure time physical activity with accelerometer (Spearman’s ρ=0.31) and 
maximal oxygen consumption (VO2max) (ρ=0.46), but no significant correlation in the case of 
light leisure time physical activity179.  The instrument has also been validated against the long 
International Physical Activity Questionnaire (IPAQ-L), VO2max, anthropometric 
measurements and serum lipids in a multi-linguistic suburban population in Norway180. Hard 
leisure time physical activity showed weak, but consistent correlations with IPAQ-L, VO2max, 
anthropometric measurements and serum lipids in both men and women, but light physical 
activity showed consistent correlations only among women. There are problems associated 
with patient recollection and assessment of the amount of physical activity performed during 
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the last year. This questionnaire has not been validated in obese individuals, and such 
individuals seem to overreport the amount of physical activity undertaken171. In the present 
study (paper III) most of the patients who completed the interventions (85 %) reported their 
highest light physical activity scores (≥3 hours/week) in the final year of the study. 55 % of 
completing patients reported the highest score (≥3 hours/week) of vigorous physical activity. 
The questionnaire’s apparent limitation as a means of assessing physical activity level may 
weaken the credibility of our results, and as a consequence interpretation of these data should 
be undertaken with caution.  
 
5.2 In the context of other studies 
 
5.2.1 Paper I 
Lifestyle intervention and body weight reduction 
Patients in the ILI-group achieved a 1-year 11 % weight loss. This is comparable with the 
results of previous lifestyle intervention studies (6-16 %)106-112, 181-183. Further, 48 % of the 
patients reached the treatment goal of ≥10 % weight reduction from baseline, and 13 % 
achieved ≥20 % reduction.  These results are inferior to those from a Norwegian study where 
70 % and 23 % of the morbidly obese patients in an intermittent residential program achieved 
≥10 % and ≥20 % reduction of body weight, respectively107. The intermittent residential 
program was more intensive in terms of duration, and patients in this study were heavier and 
had a larger percentage of men than our study, which may partly explain the difference.  By 
contrast, a very large US-study (Look Ahead) of overweight and obese diabetic patients 
reported 38 % of patients achieving a ≥10 % reduction of bodyweight after ILI111. This is 
lower than our results of 48 % of patients achieving a ≥10 % weight loss after 1 year. 
However, the intervention in this study was less intensive in terms of number of treatment 
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days and the use of mainly non-supervised physical exercise. In addition, the population was a 
diabetic one and had a lower baseline body weight compared to the population in our study. 
The patients in the MLI-group achieved a 2 % weight reduction, which might seem low 
compared with our treatment goal of a long-term weight loss of at least 5-10 %77. However, 
this result is comparable with results from similar interventions110, 111, but smaller than a 5 % 
weight loss after a more intensive outpatient treatment for 6 months107. A proportion of 16 % 
of patients in the MLI group achieved a weight loss ≥10 %, and 3 % a weight loss ≥20 %, 
which is large compared to a similar intervention111 . Compared with these results, our 
treatment goal of at least 5-10 % weight loss after MLI seems to be somewhat optimistic.  
 
Lifestyle intervention and change in physical activity level 
Paper I shows that patients in the ILI-group increased the amount of time engaged in both 
physical activity above 3 and 5 METs, while there was no significant changes after the MLI-
program. These results indicate that more patients either increased or maintained their 
physical activity level, compared to the proportion which became less active. These trends are 
in accordance with the 1-year results of a partly residential ILI including Norwegian morbidly 
obese patients with a comparable weight loss109. However, the increase in amount of time 
engaged in physical activity in our study is in contrast to another Norwegian study measuring 
physical activity level with accelerometer in morbidly obese patients before and after an 
intermittent residential weight loss intervention. The study demonstrated a significant increase 
in time spent in moderate to vigorous physical activity after 4 weeks of intervention. But 
despite a comparable weight loss after 1 year, the study found no significant difference in 
physical activity level181. In our study we used a self reported questionnaire to measure 
physical activity, and one possible explanation for the different findings in terms of physical 
activity level might be related to the different methods used (accelerometry) to measure 
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physical activity. However, a shorter intervention and smaller sample size than the ILI 
discussed in this thesis could also partly explain the difference.  
 
Lifestyle intervention and change in HRQL 
In paper I, the MLI-group had lower scores on the mental- and emotional dimensions of 
HRQL at baseline. One might argue that the lower HRQL in the MLI-group might be 
explained by a higher proportion of women, which are known to have lower HRQL than 
men66, 184. However, post-hock analyses reveals that there were no significant differences 
between men and women in either the physical-, mental- or emotional dimensions of HRQL 
in either the ILI-group, MLI-group or both groups combined. 1 year post ILI we found 
significantly larger improvements in the physical- , mental- and emotional dimensions of 
HRQL than 1 year post MLI.  The differences between groups were most pronounced in the 
emotional dimension, but were also significant in both the physical and mental dimensions. 
The results from the present study are concur partly with the results from a study comparing 
changes in HRQL after GBS and a partly residential ILI in morbidly obese patients in 
Norway68.  In this study HRQL was measured using SF-36 and OWLQOL-17. The authors 
demonstrated a significant improvement in both the physical-, mental- and emotional 
dimensions, with ES 0.47, 0.32 and 0.67 respectively. The changes in the physical and 
emotional dimension were comparable, while the changes in the mental dimension were lower 
than in our study. Since the emotional dimension of HRQL was measured using the same 
instrument and the patients were comparable, the differences may partly be explained by 
differences in the interventions.   
In accordance with our results, Faulconbridge et al. found improvement in both the physical- 
and mental dimensions of HRQL after 1 year of lifestyle modification in morbidly obese 
patients185. Patients in the MLI-group did not achieve improvements in either physical or 
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mental dimensions, but rather only on the emotional dimension of HRQL. This contrasts with 
a small randomized controlled trial of morbidly obese diabetic patients which compared  
changes in HRQL between GBS and a lifestyle intervention186. After 12 weekly group 
sessions with supervised group exercise and nutritional education, followed by monthly 
counseling for the reminding of the year, patients achieved improvement in both the physical 
and mental dimension of HRQL as measured by SF-36. This contradictory finding might 
possibly be explained by a more intensive lifestyle intervention, especially the final 9 months, 
in addition to differences in terms of the type of questionnaire. In addition, there were also 
differences between the trials in terms of age, gender distribution and bodyweight. 
 
5.2.2 Paper II & III 
Short - term study (paper II) 
The short-term results presented in paper II demonstrate a significant reduction in cfPWV 
from baseline in the ILI-group only.  
Our results contrast partly with the results from a short-term (12 weeks) randomized 
controlled study of overweight and obese healthy non-smoking middle-aged volunteers, 
which showed that a hypocaloric diet intervention (1200-1500 kcal/day) with no emphasis on 
physical activity was associated with a 7 kg weight reduction and a significant reduction in 
cfPWV of 1.3 m/s187. Despite a comparable weight loss, there was a considerably larger effect 
on cfPWV compared to our study. However, in contrast to this healthy obese population, the 
participants in our study were heavier and the majority had obesity related comorbidities. The 
results from the study in Paper II indicate that a weight loss of 9 kg in the LCD group is 
insufficient to significantly reduce cfPWV in morbidly obese individuals.  
In the view of these results, we wanted in paper II to explore the determinants of changes in 
cfPWV. Post-hoc, we constructed a predictive linear regression model of 7 weeks change in 
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cfPWV (dependent) from appropriate baseline variables (independents) commonly associated 
with cfPWV changes: gender, age, history of coronary artery disease, type 2 diabetes, 
smoking, baseline MAP, baseline BMI and baseline cfPWV. Directed acyclic graphs188 and 
baseline differences between groups were used as tools to identify the variables to be included 
in this model.  After backward selection of variables in the multivariate model, only gender 
and baseline cfPWV were retained. We subsequently performed a second multiple linear 
regression analysis with 7 weeks change in cfPWV as dependent variable, and forced 
treatment-group into the model together with the remaining independent variables (from the 
backward model), namely gender and baseline cfPWV, using the enter option. According to 
the second multiple regression model, only baseline cfPWV and treatment group had 
independent significant effects on 7 weeks change in cfPWV. Squared part correlation 
coefficients showed that treatment group and baseline cfPWV explained 2 % and 24 % of the 
7 weeks change in cfPWV, respectively (table 5). 
 
Table 5. Linear multiple regression analysis using 7-weeks change in cfPWV as dependent 
variable. 
Variable Std. β-coefficients Part correlation 
squared 
p-value 
Gender 0.139 0.02 0.055 
Baseline cfPWV (m/s) -0.513 0.24 <0.001 
Treatment group 0.149 0,02 0.033 
 
Lifestyle Intervention and effects on cfPWV 
Previous studies have demonstrated beneficial short-term (7-24 weeks) effects of various 
lifestyle intervention programs on cfPWV in normal weight189, overweight190 and obese 
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populations187, 191.  The favorable short-term effects of ILI on cfPWV in the present study are 
in accordance with the results from a randomised controlled study of overweight and obese 
healthy normotensive non-diabetic, which showed an average weight reduction of -7 kg (8 %) 
and a significant reduction in cfPWV of -0.5 m/s after 6 months. In contrast to our results in 
paper III, this significant reduction was maintained after 12 months192. The ILI in this study 
consisted of a diet and physical activity intervention, with- or without sodium reduction191. 
However, compared to our study the ILI in study referred to above was less intensive in terms 
of treatment days, but had a longer time period from baseline to short-term follow-up. Further, 
the population in this study was, when compared to our own population group, younger, had a 
lesser degree of obesity, had a smaller proportion of male individuals and had less obesity 
related comorbidities, compared to the population in our study. It is likely that individuals 
with obesity related comorbidities, like the majority of our patients, have a higher frequency 
of structural changes associated with aortic stiffness in the aortic wall compared to metabolic 
healthy obese193, 194, and a potential reversal of these changes may take several years195.   
 
Long term study (paper III) 
The long-term results in paper III showed that the favorable short-term effect of ILI on cfPWV 
was temporary, and there was no significant change from baseline to 59 weeks follow up, 
despite a considerable weight loss of 12 kg (10 %) from baseline. These results are in contrast 
to a randomised controlled study of 38 obese individuals with type 2 diabetes but otherwise 
healthy, which evaluated the effect of a behavioral weight loss intervention program 
combined with either orlistat or placebo. The intervention included an energy restriction of 
approximately 500 kcal per day and the participants were encouraged to undertake 40-60 min 
of moderate intensity physical activity most weekdays. Independent of orlistat the participants 
showed an average weight reduction of 10 kg (8 %) and a reduction of cfPWV of 0.5 m/s after 
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1 year of ILI154.  However, compared to our study this population consisted of individuals 
with a lesser degree of obesity at baseline and a lesser degree of obesity related comorbidities 
(except from type 2 diabetes). Our long-term results did not confirm the results from a study 
of 49 healthy overweight to severe obese individuals comparing the effect of a low fat diet 
and low carbohydrate diet in terms of weight loss and reduction of cfPWV. The low 
carbohydrate diet group demonstrated a slightly larger weight reduction -14.9 kg vs -11.5 kg, 
but both groups achieved a significant reduction in cfPWV of 1.4 m/s vs 1.5 m/s, no 
significant changes between groups196. However, direct comparison between these studies is 
difficult given the differences in various degrees of obesity and the frequency of obesity 
related comorbidities. 
 
Bariatric surgery and effect on cfPWV 
After GBS, the individuals in the GBS-group in the arterial stiffness study achieved a weight 
loss of 43 kg (32 %) from baseline. To our surprise, there was no significant change in cfPWV 
after 59 weeks despite this considerable weight loss. However, a significant number of 
individuals in the GBS-group stopped taking anti-hypertensive and anti-diabetic medications 
during the study. The reduction of antihypertensive medications might partly explain the 
small increase in blood pressure and the absence of beneficial changes in aortic stiffness in the 
GBS-group, as cfPWV is partly pressure dependent. Anti-hypertensive medications have the 
potential to reduce aortic stiffness beyond the blood lowering effect197. A reduction in the use 
of metformin might also have worked against a weight loss induced decline in cfPWV198.  
Our results contrast with those from a study of obese healthy adults which aimed to 
investigate the effect of weight loss on aortic PWV, demonstrating a beneficial long-term 
effect on PWV after bariatric surgery199. However, in the aforementioned study aortic PWV 
was measured at the ascending-, descending aorta and the aortic arch. In addition, 
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measurements were performed using magnetic resonance imaging -the use of different 
locations and methods to measure aortic PWV makes it difficult to compare. In contrast to 
this obese but healthy population, the population in our study consisted of treatment seeking 
morbidly individuals, with a majority having obesity related comorbidities.  
 
Impact of weight loss on changes in cfPWV according to treatment group 
The lack of a reduction in cfPWV despite a considerable weight loss in both groups was 
somewhat surprising. However, subgroup analyses demonstrated that weight loss and reduced 
WC were associated with long-term decreasing cfPWV in the ILI-group. By contrast, and to 
some surprise, weight loss was associated with increasing cfPWV in the GBS-group (figure 
14, results). In order to explore the impact of ILI and GBS on cfPWV further we performed a 
multiple linear regression analyses with long-term cfPWV-changes as dependent variable, and 
age, gender, history of coronary artery disease, and baseline values of BMI, MAP, heart rate, 
cfPWV and anthropometric parameters as explanatory variables. The regression analyses did 
not reveal any significant association between weight loss in terms of reduction in body 
weight, BMI and waist circumference. This is in accordance with the negative findings after 
lifestyle intervention in the SAVE trial191. However, the negative associations between 
changes in cfPWV (dependent) and changes in WC, BMI and body weight remained 
statistically significant (all p<0.006) in the GBS-group. This association was somewhat 
surprising and difficult to explain. Given the well known limitations of post-hoc subgroup 
analyses, this finding should, however, be interpreted with caution200. One idea might be that 
the massive weight loss in the GBS-group may lead to a reflex increase in arterial resistance 
as the hyporesponsive baroreflex caused by obesity related chronic vasodilatation is 
abolished201. 
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Possible mechanisms for changes in arterial stiffness 
Aortic arterial stiffness is influenced by both functional and structural factors193, 194, 202, 203. 
Three primary elements of the arterial wall are considered to determine arterial stiffness: first, 
the proportion of collagen and elastin; second, fractures of elastic lamella and the cross-
linking of collagen and advanced glycation end-products; and third, the vasoconstriction 
exerted by smooth muscle cells193, 194. The first two elements are considered structural, with 
changes occurring over a period of years195, and will contribute to early vascular aging 
(EVA)204-206. By contrast, vasoconstriction by vascular smooth muscle is a functional change 
that may occur very rapidly. In addition, other factors like adrenerg activity and aerobic 
exercise may modulate aortic compliance within a short space of time193, 194. Heart rate, blood 
pressure, change in muscle mass and insulin resistance may also affect aortic arterial stiffness, 
and these changes occur over a short period of time and well within the timeframe of the 
interventions in paper II. Further, one might speculate that the lack of change in cfPWV after 
59 weeks despite a considerable weight loss might be explained by the more slowly occurring 
structural changes over a longer period of time.  
 
Heart rate  
Heart rate affects arterial mechanics, but has a greater effect on elastic arteries than muscular 
arteries207. The effect of heart rate might possibly be explained by the viscoelastic properties 
of the arterial wall, as there is an increased arterial stiffness as a result of an increased rate of 
stretching and vice versa50. A post-hoc analysis on the short-term results of the arterial 
stiffness study showed that the mean (95%CI) reduction in heart rate was larger in the ILI-
group after adjustment for age, gender and baseline heart rate, 5.2 (2, 8) beats/min, p=0.020. 
However, the reduction in heart rate had no significant effect in the fully adjusted ANCOVA 
model, p=0.123. In contrast, the long-term results showed that the participants in the GBS-
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group had the largest reduction of heart rate 11.7 (10, 14) beats/min, p<0.001. A post-hoc 
analyses showed that the reduction in heart rate had a small but significant effect in the fully 
adjusted ANCOVA model and explained 5 % of the variance in cfPWV after 59 weeks (Partial 
Eta Squared 0.047, p=0.008).  
 
Blood pressure 
Blood pressure affects aortic PWV. The short term results (paper II) show a reduction of 
systolic blood pressure in both the ILI- and LCD-group, but only the ILI-group achieved a 
significant reduction in diastolic blood pressure. In contrast, the long term results (paper III) 
showed that there was no significant change in blood pressure in the ILI-group, and only a 
significant reduction in systolic blood pressure in the GBS-group. The blood pressure variable 
that best reflects aortic stiffness is not systolic or diastolic blood pressure, but rather pulse 
pressure208, 209. A post-hoc analysis showed that neither change in mean arterial pressure nor 
change in pulse pressure after 7 weeks had a significant effect on cfPWV in the fully adjusted 
ANCOVA model, p=0.364, and p=0.900, respectively. However, after 59 weeks both change 
in pulse pressure and change in MAP had a small but significant effect on cfPWV in the fully 
adjusted ANCOVA model Partial Eta Squared 0.104, p<0.001 and Partial Eta Squared 0.168, 
p<0.001, respectively. After 59 weeks change in pulse pressure and change in MAP explained 
10 % and 17 % of the variance in cfPWV, respectively. 
 
Change in muscle mass and insulin resistance 
Age related reduction in muscle mass is associated with increased arterial stiffness210, 211. Loss 
in muscle mass can reduce insulin sensitivity212 , which contributes to a increase in arterial 
stiffness independent of blood pressure213. One of the main mechanisms involved here is the 
formation of advanced glycation end-product on the arterial wall, leading to cross-linking of 
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collagen molecules which in turn may lead to loss of collagen elasticity and a subsequent 
increase in arterial stiffness214. 
After 7 weeks there was a significant loss of muscle mass among individual in both groups, 
but significant larger loss after LCD, p≤0.001. However, after 59 weeks there was only a 
significant loss of muscle mass among individuals in the GBS-group, and also a significant 
between groups difference, p<0.001. There were no significant differences between groups in 
terms of insulin sensitivity after 7 weeks. However, after 59 weeks there were significant 
reductions in terms of insulin, glucose, HbA1C and HOMA-IR in both groups, but the 
reductions were more pronounced among individuals in the GBS-group, all p≤0.002. 
Accordingly, the loss of muscle mass, especially in the GBS-group, has the potential to 
explain some of the absence of reduction of cfPWV after 59 weeks. However, the significant 
reduction in insulin, glucose, HbA1C and HOMA-IR suggest the effect of loss of muscle 
mass on cfPWV to be limited. 
 
Physical activity 
Several studies indicate that physical activity has a direct effect on arterial compliance 
independent of changes in body weight, blood pressure, lipids and heart rate215-217. However, 
the mechanisms behind this are not completely understood. Mechanisms induced by exercise 
might be: deformation of the vessel which may combat collagen cross-linking, vascular 
smooth muscle cells relaxation216.  Several mechanisms may contribute to vascular smooth 
muscle cell relaxation, such as increased arterial wall sheared stress and bioactivity of nitric 
oxide, and reductions in vasoconstrictor tone, oxidative stress and inflammation217, 218. The 
short-term changes after aerobic exercise may suggest that these changes are of a more 
functional than structural character. Our short term results indicate that the difference in 
reduction of cfPWV between the treatment groups was largely independent of weight loss, 
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insulin sensitivity, heart rate, blood pressure and lipids. One might speculate that the between-
group difference in change in cfPWV is related to physical activity, which is a main difference 
between the two interventions. The physical activity level in an average week over the course 
of the last year was measured with a self reported questionnaire. According to these results 
there were no significant differences in either light physical activity, vigorous physical 
activity or occupational physical activity. Even though we do not have any measures of 
changes in physical activity levels in either of the groups, we know that during the first 12 
weeks of the intervention patients participated in 6 supervised exercise sessions each week, 
which contrasts with those individuals in the LCD-group. One explanation might be that the 
physical activity level among participants in the ILI-group decreased, contributing to the lack 
of a reduction in cfPWV among patients in the ILI-group. In order to investigate the impact of 
physical activity and physical fitness on arterial stiffness, long-term studies with objective 
measurement of physical activity level (accelerometry) and physical fitness (indirect 
calorimetry) are needed.  
 
Change in use of anti-diabetic and anti-hypertensive drugs 
As was discussed earlier, cfPWV is partly pressure dependent, with a change in anti-
hypertensive medication having the potential to affect cfPWV.  There were no significant 
differences in usage of anti-hypertensive or anti-diabetic medication between groups at 
baseline, and during the first 7 week one individual in each group stopped using hypertensive 
medications. In the same period there were no changes in use of anti-diabetic medications 
among individuals in the ILI-group, while there were 2 who stopped using Glitazone, 5 who 
stopped using sylfonylurea and 1 who stopped using metformin.  At 59 week follow-up there 
was a significant reduction in patients treated with anti-hypertensive or anti-diabetic drugs 
among patients in the surgery group. Specifically, the use of RAAS-inhibitors, beta-blockers, 
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diuretics, sulfonylurea and metformin reduced significantly, all p<0.032. There were no 
significant changes in statins in either group. As anti-hypertensive medications have the 
potential to reduce aortic stiffness beyond the blood pressure lowering effect197, the reduction 
in usage of anti-hypertensive medications might explain some of the small increases in blood 
pressure and the absence of beneficial changes in cfPWV seen in the GBS-group despite their 
substantial weight loss.  Further, the use of metformin198, 219 and atorvastatin220 have been 
associated with reduced arterial stiffness. The discontinuation of metformin might also have 
mitigated any weight loss induced decline in cfPWV in the GBS-group. 
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Chapter 6. Clinical implications 
 
 
Paper I 
In paper I we demonstrate that a combination of moderate energy restriction and supervised 
physical activity (ILI) was superior to a less intensive lifestyle intervention in terms of 1-year 
weight loss and health related quality of life in treatment seeking morbidly obese patients. 
According to our results, the MLI-programme, as performed in present study, may be 
insufficient in itself to induce meaningful weight loss in morbidly obese patients. 
Accordingly, the local obesity center has implemented changes in the MLI programme in 
order to improve it`s results.  
 
Paper II 
Even though energy restriction is one of the cornerstones of obesity treatment and has many 
positive metabolic effects, the short-term reduction of cardiovascular risk is likely to be 
greater when energy restriction is combined with physical activity. We demonstrate that in 
spite of a slightly lower 7-week weight loss and comparable effects on blood pressure, insulin 
sensitivity and lipids, patients in the ILI-group achieved a significantly larger reduction in 
cfPWV compared to patients in the LCD-group. These results indicate that in treatment 
seeking morbidly obese individuals a combination of caloric restriction and supervised 
physical exercise might be a more effective combatant of aortic arterial stiffness than isolated 
caloric restriction. Whether this beneficial effect transforms into lower cardiovascular 
morbidity and mortality is unknown. 
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Paper III 
In paper III, we show that the short-term effects demonstrated in paper II were of a temporary 
character, and one may speculate as to whether these changes were caused by adaptations of 
the functional elements of the aorta. In order to achieve persistent adaptations of the 
functional elements of the aorta caused by for instance physical exercise, it is likely that the 
exercise needs to be maintained. In addition, some of the long-term effects of cfPWV are 
likely to be the results of changes in structural elements of the aorta, such as changes in the 
collagen-elastin ratio, fractures of elastic lamella and the cross-linking of collagen. These are 
changes that are modified over a period of years. In order to give any definitive 
recommendation, further verification and follow up for several years is needed. 
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Chapter 7. Summary 
 
Paper I 
We compared the effectiveness of an intensive lifestyle intervention programme (ILI) at a 
tertiary care centre and a moderate lifestyle intervention programme (MLI) conducted at a 
secondary care centre in morbidly obese individuals. The ILI was associated with a 
significantly larger weight reduction and greater improved physical, mental and emotional 
dimensions of health related quality of life than the MLI.  
 
Paper II 
We compared the 7-week effect of a low calorie diet and an ILI program on aortic arterial 
stiffness in morbidly obese individuals. Individuals in the ILI-group achieved a significantly 
greater reduction in cfPWV compared to the LCD-group, indicating that short-term moderate 
caloric restriction (minus 1000 kcal/day) combined with supervised physical exercise might 
be superior to an isolated more pronounced caloric restriction (Low calorie diet < 900 
kcal/day) among Norwegian treatment seeking morbidly obese individuals. 
 
Paper III 
We compared the 1-year effect of an ILI-program and a surgical weight loss program on 
cfPWV in morbidly obese individuals. There were no significant changes in cfPWV after either 
ILI or GBS after 59 weeks, despite a large weight loss in both groups. Our findings indicate 
that weight loss, either induced by GBS or ILI, has no significant long-term effect on aortic 
stiffness in Norwegian treatment-seeking morbidly obese individuals. 
 
  
83 
Chapter 8. Topics for future research 
 
Long -term effectiveness of intensive lifestyle intervention 
The one year effect of intensive lifestyle intervention in terms of changes in body weight, 
HRQL and physical activity level needs to be confirmed in well designed and carefully 
conducted randomised controlled trials and observational studies (e.g. comparative 
effectiveness research) with long-term follow up.  
 
Measurement of physical activity and physical fitness. 
Further studies of physical activity in morbidly obese individuals should use accelerometry in 
order to achieve an objective measurement of physical activity level.  
 
Aerobic exercise and aortic PWV 
Paper II demonstrated a significant reduction of aortic PWV after 7 weeks of lifestyle 
intervention consisting of aerobic exercise and caloric restriction. Paper III showed that these 
favorable changes were of temporary character. One might argue that these favorable changes 
in aortic PWV might be sustained if the physical activity level, in terms of intensity, 
frequency and durations were maintained. One future topic is to address the functional 
adaptations to sustained physical activity level and the possible effect on aortic PWV in 
morbidly obese individuals. 
 
Weight loss and long-term changes in aortic PWV. 
Paper III demonstrated that there were no significant long-term effects on aortic PWV after 
either ILI or GBS, despite considerable weight loss in both groups.  A major part of the long-
term changes in aortic stiffness are probably caused by structural changes and develop over 
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years, and these structural changes might develop beyond the timeframe of the studies 
presented in this thesis. In order to investigate the impact of weight loss on the structural 
changes in the aortic wall long term studies are required.  
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Arterial Stiffness, Lifestyle Intervention
and a Low-Calorie Diet in Morbidly Obese
Patients—A Nonrandomized Clinical Trial
N. Nordstrand1,2, E. Gjevestad1, J.K. Hertel1,4, L.K. Johnson1, E. Saltvedt1, J. Røislien1,3 and J. Hjelmesæth1
Objective: Arterial stiffness is an independent predictor of cardiovascular morbidity and mortality. This
study aimed to compare the 7-week effect of a low-calorie diet (LCD) and an intensive lifestyle
intervention program (ILI) on arterial stiffness in morbidly obese individuals.
Design and Methods: Nonrandomized clinical trial. The LCD provided 900 kcal/day, and participants in
the LCD group were instructed to maintain their habitual physical activity level. The ILI included two 90-
min supervised training sessions 3 days a week at moderate to high intensity (4-8 METs) and a caloric
restriction of 1000 kcal/day.
Results: A total of 179 individuals completed the study, 88 (56 women) in the ILI group and 91 (57
women) in the LCD group. High-fidelity applanation tonometry (MillarV
R
, SphygmocorV
R
) was used to
measure carotid-femoral pulse wave velocity (PWV). After adjustment for relevant confounders, the ILI
group had a significantly greater reduction in PWV than the LCD group; 0.4 (0.6, 0.1) m/s, P ¼
0.004. When compared to the LCD group, the ILI group showed a larger reduction in systolic and
diastolic blood pressure 5 (9, 1) and 5 (7, 2) mmHg, P ¼ 0.038 and P  0.001 respectively,
whereas no difference was observed regarding pulse pressure, P ¼ 0.661. No significant differences
between groups were found regarding the loss of fat mass, P ¼ 0.259, but the loss of muscle mass was
larger in the LCD group, 0.8 (0.5, 1.1) kg, P  0.001.
Conclusion: Despite the limitations of a nonrandomized design, our findings indicate that for morbidly
obese individuals a moderate caloric restriction combined with aerobic physical exercise is associated
with a greater decline in PWV than a LCD alone.
Obesity (2013) 21, 690-697. doi:10.1002/oby.20099
Background
Obesity is a world-wide health concern (1) and imparts a degree of
cardiovascular risk similar to that associated with hypertension, hy-
perlipidemia, and smoking (2). New insights from the National
Health and Nutrition Examination Survey indicate that the preva-
lence of obesity has stabilized during the last decade, but there is
evidence that within the obese population, the prevalence of morbid
obesity is increasing at a high rate (3,4).
The cornerstone of obesity management is weight loss. Any inter-
vention with the intention to cause weight loss must tip the balance
between energy intake and expenditure to be successful. Official
recommendations state that a reduction in energy intake of
500 kcal below energy expenditure per day will result in a weight
loss of 0.5 kg per week. There is, however, evidence that the sim-
plicity of the shift in energy balance could be misleading and might
not be adaptable to a real-life situation. The weight response to ca-
loric restriction is slow, and to reach steady-state weight, an individ-
ual must comply with the dietary intervention for a long time.
Purely dietary interventions will be more time consuming and
demanding in morbidly obese individuals than in less obese individ-
uals (5). It is therefore important to investigate whether or not there
are supplementary efforts (other than a strict diet) that can attenuate
the cardiovascular risk associated with morbid obesity. Several lines
of evidence indicate that aerobic physical activity might decrease
cardiovascular risk in obese individuals (6,7). Whether or not this is
true for morbidly obese individuals is unknown.
Arterial stiffness assessed by aortic pulse wave velocity (PWV) is
an independent predictor of cardiovascular morbidity and mortality
(8), and PWV is increasingly recognized as a valid surrogate end-
point of cardiovascular disease (9,10). In healthy young adults,
arteries stiffen when weight is gained and soften with weight loss.
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(11) Recent evidence suggests this to hold true in overweight and
obese middle-aged individuals (12,13). It has been shown that when
matched for age, PWV is 0.5 m/s higher in obese compared with
non-obese. This increase in PWV is equivalent to 5-10 years of age-
ing (14). It has also been shown that aerobic physical activity is
associated with the prevention of arterial stiffening (15), and more-
over that aerobic training can reduce arterial stiffness (16).
The measurement of PWV is generally accepted as a simple, non-
invasive, robust, and reproducible method to determine arterial stiff-
ness and is considered to be the golden standard method for evalua-
tion of arterial stiffness (17,18). To the best of our knowledge, the
current study is the first to investigate how a low-calorie diet (LCD)
and intensive lifestyle intervention (ILI) affect arterial stiffness in a
morbidly obese population.
The primary objective of this study was to compare the effect of a
LCD and an ILI program on arterial stiffness in morbidly obese
individuals. Our main hypothesis was that a 7-week ILI program
consisting of aerobic endurance training 3 days a week and a moder-
ate daily caloric restriction would have a greater effect on arterial
stiffness than a 7-week LCD.
We further hypothesized that the loss of skeletal muscle mass and
fat mass would be greater in the group subjected to a LCD.
Methods
Study design
This is the first part of a nonrandomized clinical trial comparing the
effects of an intensive lifestyle modification program, a LCD, and
bariatric surgery on arterial stiffness in morbidly obese patients.
Results from the baseline cross-sectional analysis have been pub-
lished elsewhere (19). (ClinicalTrials.gov Identifier NCT00626964).
Setting
The study was performed at a tertiary care centre (the Morbid Obesity
Centre, Vestfold Hospital Trust, Tønsberg, Norway) between February
2008 and February 2011. Before inclusion patients were either assigned
to a comprehensive lifestyle modification program at the Clinic of
Physical Medicine and Rehabilitation, Vestfold Hospital Trust, or to a
LCD followed by bariatric surgery at the Morbid Obesity Centre.
Participants
All participants were recruited from our tertiary care centre and had
to reside within 100 km of either the hospital for rehabilitation or
our clinic. The patients in the ILI group were all selected from sub-
jects that had registered for participation in a standardized health
promotion and weight reduction program at the hospital for rehabili-
tation. Participants in the LCD group were selected from patients
due to undergo bariatric surgery at our hospital. The decision
regarding the type of intervention was made prior to inclusion to
our study and was not a part of our protocol.
Inclusion criteria were body mass index (BMI)  40.0 kg/m2 or
BMI  35.0 kg/m2 accompanied by one or more obesity-related
comorbidities.
Exclusion criteria were uncompensated heart failure, cardiac arrhyth-
mias, unstable angina, end-stage renal disease, known bleeding dis-
turbances, serious psychiatric disorders, serious eating disorders,
cardiac pacemakers, intra-cardiac devices, cerebrovascular event, or
a myocardial infarction within the last 6 months.
The study was approved by the regional ethics committee of the
Southern Norway Regional Health Authority (code: S-05175) and
was performed in accordance with the Declaration of Helsinki (20).
Written informed consent was provided by all participants.
Intensive lifestyle intervention
Each of the ILI groups comprised of 12-14 patients. The baseline
individual energy expenditure was calculated according to Scho-
field’s equation (21). Schofield’s equation uses information pertain-
ing to the patient’s gender, age, and body weight to calculate resting
metabolic rate (BMR). To calculate total energy expenditure, BMR
was multiplied with a physical activity factor of 1.4, which is con-
sidered the increased energy cost of sedentary behavior (22). All
participants received a dietary plan with an energy restriction of
1000 kcal/day in relation to calculated baseline energy expenditure,
otherwise according to Norwegian nutritional guidelines (23).
Individuals in the ILI group were followed for 3 days per week during
an intervention period of 7 weeks. Each day of intervention lasted 6 h
and included two 90-min supervised training sessions, educational ses-
sions regarding nutrition and physical activity. The first of the two
supervised exercise sessions consisted of weight-bearing activities,
such as walking, Nordic-walking, running, ballgames, resistance train-
ing, and other various exercises. The second exercise session consisted
of water aerobics, swimming, and other water-based physical activ-
ities. The main aspect of the physical training was aerobic endurance
training with moderate (four metabolic equivalents of task (METs)) to
high intensity (eight METs). The resistance training was performed
with 15-20 repetitions per exercise (24).
Study participants also had individual sessions with qualified person-
nel who used a client-centered counseling style known as motiva-
tional guidance techniques (25) to invoke behavioral change within
the participants.
Low calorie diet intervention
The LCD consisted of crisp bread combined with low-fat products
for breakfast, lunch, and supper. Dinner consisted of fish, poultry, or
lean meat combined with potatoes, rice, or pasta and vegetables.
These ingredients did not provide >900 kcal per day, of which 37%
of the energy came from protein, 43% from carbohydrates, and 20%
from fat. Patients were allowed to increase the size of their meal
using vegetables and water. Daily intake of a multivitamin/mineral
supplement was recommended. Participants in the LCD group were
instructed to maintain their habitual physical activity level through-
out the intervention. The study participants were not allowed to
attend other dietary or physical interventions prior to or during the
7 weeks of intervention in the present study.
Outcomes
The main outcome variable was the 7-week change in arterial stiff-
ness measured by PWV. Secondary outcomes were changes in
weight, body composition, systolic and diastolic blood pressure, and
pulse pressure.
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Data sources and measurements
All participants underwent a medical examination performed by a phy-
sician and a trained nurse. All measurements were performed after an
overnight fast. Participants were instructed to withdraw from their pre-
scribed medications and smoking prior to the examination on the day
of testing. Blood was collected by venipuncture on the day of medical
examination. Weight and height were measured with patients wearing
light clothing and no shoes. BMI was calculated as weight in kilograms
divided by the square of the height in meters. Waist circumference
(WC) was measured midway between the 12th rib and the iliac crest.
Blood pressure was measured after 5 min of rest using an electronic
auscultatory blood pressure recorder with an appropriately sized cuff
based on an arm circumference measurement (Dinamap
VR
, ProCare
Series, G.E. Medical Systems) with the patient sitting in an upright
position. Three measurements were recorded. The average of the sec-
ond and third recordings was used in the blood pressure analysis. Bioe-
lectrical impedance measures were collected using the Inbody 720,
Body Composition Analyzer, Biospace Co. Ltd. Arterial hypertension
was defined by either, a systolic blood pressure 140 mmHg, diastolic
blood pressure 90 mmHg, or the use of antihypertensive medication.
Ischemic heart disease was defined as a history of stable coronary artery
disease, percutaneous coronary intervention, coronary artery bypass
graft surgery, or myocardial infarction. Mean arterial pressure (MAP)
was calculated as [(diastolic pressure  2) þ systolic pressure]/3 (11).
The Sphygmocor system (Artcor, Sidney, Australia) and a single
high-fidelity applanation tonometer (Millar
VR
) were used to measure
PWV. Pulse waves were obtained sequentially from the carotid and
femoral artery. The locations of the sternal notch, carotid pulse, and
femoral pulse were located. We placed tape directly above these
spots with the patient in horizontal position to get a true linear mea-
sure. The distance was calculated as the distance between the carotid
notch and the femoral artery minus the distance between the carotid
notch and the carotid artery (18). The PWV was calculated from the
transit time and the distance between these two arterial sites, deter-
mined in relation to the R-wave of the ECG, with patients lying in a
horizontal position. Blood pressure was measured before every re-
cording and entered into the Sphygmocor recorder to secure valid
recordings with similar blood pressure. Three complete sets of data
were sampled, and the average value was used as result.
Bioelectrical impedance analysis was obtained using Inbody 720, Body
Composition Analyzer, Biospace Co. Ltd. Each patient was undressed
except for underwear and placed in an upright position on the body
composition analyzer. All jewelry and wrist-watches were removed
before recording. The InBody 720 uses the segmental BIA method to
examine the body as five cylinders (four limbs and a trunk) and meas-
ures impedance in these parts separately. It also uses electrical current
at multi-frequency (5, 50, 250, 500, and 1000 kHz) to estimate the
amount of extracellular and intracellular water. Homeostasis Model
Assessment Insulin Resistance (HOMA- IR) was calculated as [fasting
serum glucose (mmol/L)  fasting serum insulin (pmol/L)]/135 (26).
Low-density lipoprotein cholesterol (LDL) concentrations were esti-
mated by the Friedewald equation: LDL cholesterol ¼ Total cholesterol
 HDL cholesterol  (0.45  triglycerides) (27). LDL cholesterol was
not calculated if S-triglycerides were <0.2 mmol/L or 5 mmol/L.
Laboratory analyses
Analyses of serum glucose and blood lipids were performed using
dry reagent slide technology on the Vitros FS 5.1 (Ortho-Clinical
Diagnostics, New York). Glycated hemoglobin (HbA1c) was ana-
lyzed using high-performance liquid chromatography on Tosoh
HLC-723 G7 (Tosoh Corporation, Tokyo, Japan). Sera for analysis
of insulin were stored at 20C and analyzed within 1 week of
blood sampling (Linco Research Inc., St. Charles, MO).
Sample size
The present study is the first part of an ongoing non-randomized
clinical trial. The sample size was calculated based on Barinas-
Mitchell et al.’s (28) study, which showed that a mean weight
reduction of 8% resulted in 1.4 m/s mean reduction in PWV in over-
weight individuals with diabetes. From this, we hypothesized that
the mean PWV would be 8.2 m/s in both groups at baseline and that
a 1-year weight loss of 8% in the ILI group would lead to a mean
(SD) of 1.4 (2.8) m/s reduction in PWV. The expected weight loss
following gastric bypass surgery is roughly three times as high, and
we assumed that the mean reduction in PWV would be 2.8 m/s.
Accordingly, at least 120 individuals had to complete the study to
show a statistically significant difference between the two groups at
a power of 80% (a ¼ 0.05). To allow for a drop-out rate of <40%,
we decided to include 200 patients (100 in each group).
Statistical methods
Data are presented as mean (SD) or number (%) unless otherwise
specified. Skewed data were transformed using natural logarithms to
approximate normality. Differences between groups at baseline were
analyzed using independent samples t-test or Fisher’s exact test.
FIGURE 1 Flow chart.
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Spearman’s rank correlation was used to assess the bivariate associa-
tion between weight loss, the change in fat mass, and the change in
PWV. Within-group changes from baseline to follow-up were ana-
lyzed using paired samples t-test. Differences between groups in
PWV at follow-up were analyzed using analysis of covariance
(ANCOVA) including age, gender, MAP, baseline BMI, history of
coronary artery disease, and baseline value of the dependent variable
as covariates (11). Directed acyclic graphs (29) and baseline differ-
ences between groups were used as regression modeling tools to
identify the confounding factors to be included as covariates in the
ANCOVA. The model was further adjusted for change in MAP and
reduction in weight to explore if the specific intervention was inde-
pendently associated with the measured effect variable beyond the
effect mediated by weight loss or reduction in MAP. Differences
between groups in systolic blood pressure, diastolic blood pressure,
and pulse pressure were analyzed using ANCOVA including age,
gender, history of coronary artery disease, baseline BMI, and base-
line value of dependent variable as covariates.
Results
During the inclusion period, 239 individuals were eligible for inclu-
sion, 39 declined to participate leaving 200 individuals who
accepted our invitation to participate in the study (Figure 1). Nine
individuals in the ILI group found the activity level too demanding
and withdrew from the study. Twelve individuals did not complete
the study due to other reasons, leaving a total of 179 patients in the
present analysis, 88 (56 women) in the ILI group and 91 (57
women) in the LCD group (Figure 1).
The groups were not significantly different in terms of PWV, but
individuals in the LCD group were slightly younger and had higher
systolic blood pressure, pulse pressure, slightly higher body weight
and fat mass, and lower prevalence of ischemic heart disease com-
pared with the ILI group (Table 1). Our records show that 40 (46%)
of the individuals in the ILI group and 31 (34%) in the LCD group
used antihypertensive medication at baseline, P ¼ 0.129. The major-
ity (39 out of 40 and 30 out of 31) were still taking antihypertensive
medication at follow up.
Changes in arterial stiffness and blood pressure
The ILI group had a statistically significant reduction in mean
(95 % CI) PWV of 0.6 (0.8, 0.4) m/s, P  0.001 (Figure 2a). In
contrast, the reduction in PWV observed in the LCD group was not
statistically significant, 0.2 (0.4, 0.0) m/s, P ¼ 0.064. After adjust-
ment for age, gender, baseline MAP, baseline BMI, history of coronary
artery disease, and baseline PWV, the decline in PWV was signifi-
cantly larger in the ILI group than in the LCD group, between-group
difference 0.4 (0.1, 0.6) m/s, P ¼ 0.004 (Figure 2b). The larger decline
in PWV observed in the ILI group (compared to the LCD group) was
slightly attenuated but still significant after further adjustment for
change in weight and change in MAP 0.3 (0.1, 0.6) m/s, P ¼ 0.019.
Both interventions led to a statistically significant reduction in systolic
blood pressure, but only the ILI group showed a significant reduction
in diastolic pressure (Figure 3a and b). When compared to the LCD
group, the ILI group showed a larger decline in systolic and diastolic
blood pressure after adjustments for age, gender, baseline BMI, his-
tory of coronary artery disease, baseline value of the dependent vari-
able, and between-group difference: 5 (1, 9) and 5 (2, 7) mmHg; P ¼
0.038 and P  0.001, respectively. The same adjustments were made
in terms of decline in pulse pressure and showed no significant differ-
ence between groups, P ¼ 0.661 Table 2.
Weight, body composition, glucose metabolism,
and lipids
Body weight and WC were significantly reduced after both interven-
tions (Table 3). After adjustments for age, gender, and baseline
weight, a significantly larger weight loss was shown in the LCD
group, between-group difference of 1.5 (2.6, 0.5) kg, P ¼ 0.006.
In contrast, the adjusted reduction of WC was not significantly
TABLE 1 Baseline demography and differences between
groups in anthropometric measures, carotid-femoral PWV,
and blood pressure, medication, and glucose and lipid
metabolism
ILI LCD P
Age 45.2 (10.9) 42.3 (9.6) 0.045
Male/female 32/56 34/57 0.999
Diabetes 19 (21) 25 (27) 0.388
Hypertension 68 (77) 59 (65) 0.072
Ischemic heart disease 12 (14) 2 (2) 0.005
Smokers 14 (16) 18 (20) 0.560
Weight and anthropometric measures
Weight, kg 125.2 (20.4) 137.8 (22.4) 0.001
Body mass index, kg/m2 42.5 (5.1) 45.7 (5.5) 0.001
Waist circumference, cm 128 (13) 133 (13) 0.007
Fat mass, kg 58.3 (12.4) 66.8 (12.9) 0.001
Skeletal muscle mass, kg 37.7 (7.3) 39.8 (8.0) 0.078
PWV and blood pressure
Carotid-femoral pulse wave
velocity, m/s
8.6 (1.8) 8.7 (1.7) 0.837
Systolic blood pressure, mm Hg 146 (17) 139 (19) 0.007
Diastolic blood pressure, mm Hg 80 (11) 81 (15) 0.613
Pulse pressure, mm Hg 66 (16) 58 (16) 0.002
Medication
-Blocker 14 (16) 11 (12) 0.521
Calcium-channel blocker 10 (11) 11 (12) 0.999
Inhibitors of the RAA system 34 (39) 26 (29) 0.159
Diuretics 18 (21) 12 (13) 0.232
Statins 19 (22) 12 (13) 0.168
Glucose and lipid metabolism
Insulin, pmol/L 94.02 (53.2) 117.6 (100.1) 0.060
Glucose, mmol/L 6.0 (2.2) 6.1 (2.1) 0.516
HbA1C, % 6.0 (1.2) 6.1 (1.2) 0.789
HOMA-IR 4.09 (2.76) 5.65 (5.97) 0.057
Total cholesterol, mmol/L 5.1 (1.0) 4.9 (0.9) 0.156
LDL cholesterol, mmol/L 3.1 (1.0) 3.1 (0.8) 0.611
HDL cholesterol, mmol/L 1.2 (0.3) 1.1 (0.3) 0.074
Triglycerides, mmol/L 1.8 (1.2) 1.6 (0.9) 0.703
Number (%) or mean (SD). Independent samples t-test or Fischer’s exact test.
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different between groups, P ¼ 0.471. Bioelectrical impedance analysis
showed a significant reduction in fat mass [6.0 (6.6, 5.3) in the
ILI group and 7.0 (7.8, 6.3) in the LCD group] and skeletal mus-
cle mass [0.5 (0.7, 0.3) in the ILI group and 1.4 (1.7, 1.2)
in the LCD group], all P  0.001. After adjustments for age, gender,
and baseline value of dependent variable, the loss of skeletal muscle
mass was 0.8 (0.5, 1.1) kg larger in the LCD group, P  0.001,
whereas no differences were apparent in terms of fat mass (Figure 4).
Simple correlation analysis showed no significant associations between
change in PWV and the changes in weight (r ¼ 0.017, P ¼ 0.821)
and loss of fat mass (r ¼ 0.041, P ¼ 0.590). There were reduced
blood glucose levels for both interventions with no statistically signifi-
cant differences between groups (Table 3). There was a significantly
greater decline in total-cholesterol and triglyceride levels and a smaller
decline in HDL-cholesterol for patients in the ILI group compared to
those in the LCD group.
Discussion
Our findings demonstrate that in morbidly obese individuals, a com-
prehensive 7-week ILI program consisting of a moderate caloric
restriction (1000 kcal/day) and aerobic physical activity of moderate to
high intensity (4-8 METs) had a larger effect on arterial stiffness than
a 7-week LCD (<900 kcal/day) intervention. The greater weight loss
in the LCD group was due mainly to a significantly greater loss of
skeletal muscle mass. No significant between group differences were
evident in terms of the decline in fat mass or the reduction in WC.
Comparison with the previous studies
Some prior studies have shown that PWV can be reduced in less
obese through short-term (6 weeks to 3 month) weight reduction by
the separate use of diets (12,13) and increased aerobic physical exer-
cise (16) or a combination of the two (30). To our knowledge, there
are no studies exploring how arterial stiffness can be modified in a
population of morbidly obese subjects.
The beneficial results of ILI on PWV are in accordance with the
findings of a 1-year randomized clinical trial, which evaluated the
effect of a behavioral weight loss intervention program combined
with either orlistat or placebo in 38 obese individuals [average BMI
34.0 (5.2) kg/m2] with type 2 diabetes (28). The intervention
included an energy restriction of 500 kcal per day and participants
FIGURE 2 Changes in carotid-femoral PWV after 7 weeks of follow up. Within groups (a), adjusted difference between groups (b).
FIGURE 3 The within-group changes in systolic and diastolic blood pressure after 7 weeks of follow-up.
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were encouraged to undertake 40-60 min of moderate intensity phys-
ical activity (such as walking or cycling) most week days. Independ-
ent of orlistat, the intervention was associated with a mean weight
reduction of 7.8% (10 kg) and a 0.5 m/s reduction in PWV. As in
the present study, the changes in PWV did not correlate significantly
with weight loss. Importantly, this study differed from our own by
the inclusion of relatively few morbidly obese subjects, no super-
vised training sessions, and a longer follow-up period.
Partly in contrast with our results, a short-term (12 weeks) random-
ized controlled study of overweight and obese healthy non-smoking
middle-aged volunteers showed that a hypocaloric diet intervention
(1200-1500 kcal/day) with no emphasis on physical activity was
associated with a 7 kg reduction in weight and a significant reduc-
tion in PWV of 1.3 m/s (12). Although the weight loss was compa-
rable, the effect on arterial stiffness was more pronounced than that
in our study. It is hard to find a plausible explanation for this large
difference, particularly in view of the higher level of physical activ-
ity in our ILI group. However, direct comparison between the stud-
ies is difficult given by differences in study design, time of follow
up, and various degree of obesity among the participants.
Arterial stiffness and insulin sensitivity and
biological age
Arterial stiffness has been linked to age-related decline in muscle
mass (31,32). Loss of muscle mass is associated with reduced insu-
lin sensitivity (33), and decreased insulin sensitivity is linked to
arterial stiffness (34,35). Individuals in the ILI group conserved
more skeletal muscle mass than those in the LCD group. However,
the greater loss of muscle mass in the LCD group compared to the
ILI group did not translate into significant differences in terms of
improvements in insulin sensitivity. The current popular notion that,
in obese patients, a hypocaloric diet alone can reduce arterial stiff-
ness could not be verified in Norwegian morbidly obese patients as
the short-term LCD used failed to show any significant effect on ar-
terial stiffness. Accordingly, the improved results in the ILI group
are more likely to be mediated by the physical activity undertaken
by individuals in that group.
Arterial stiffness is regarded as a measure of premature vascular
ageing. According to the arterial stiffness reference value (36), the
baseline biologic vascular age of our study population may be esti-
mated to be 10-12 years older than it would be in normal-weight
healthy individuals of a similar age. The reduction in PWV observed
in the ILI group may translate into a reversal of age-related arterial
stiffening of 5 to 7 years (37). Our findings support the notion that
in morbidly obese individuals caloric restriction and physical activ-
ity might be preferable to weight loss by a LCD alone. Whether the
short-term decline in PWV translates into a long-term clinically sig-
nificant improvement in cardiovascular risk remains to be seen.
There are some limitations within the present study, which should be
acknowledged. The major weaknesses are the lack of randomization
TABLE 2 Adjusted within- and between-group differences in carotid-femoral pulse wave velocity and blood pressure variables
ILI LCD Adjusted difference P value
PWV, m/s 0.6 (0.8, 0.4) 0.2 (0.4, 0.0) 0.4 (0.6, 0.1) 0.004
Systolic blood pressure, mm Hg 13 (16, 11) 8 (11, 5) 5 (9, 1) 0.038
Diastolic blood pressure, mm Hg 6 (8, 4) 1 (3, 1) 5 (7, 2) 0.001
Pulse pressure, mm Hg 6 (9, 3) 7 (10, 4) 1 (5, 3) 0.661
Mean (95% CI). Analyses of covariance (ANCOVA) including age, gender, baseline BMI, baseline MAP, history of coronary artery disease, and baseline status in dependent
variable as covariates for PWV and age, gender, baseline BMI, history of coronary artery disease, and baseline status in dependent variable as covariates for systolic blood
pressure, diastolic blood pressure and pulse pressure.
FIGURE 4 The loss of skeletal muscle mass and fat mass after 7 weeks of follow-up.
Original Article Obesity
CLINICAL TRIALS: BEHAVIOR, PHARMACOTHERAPY, DEVICES, SURGERY
www.obesityjournal.org Obesity | VOLUME 21 | NUMBER 4 | APRIL 2013 695
and short follow-up time. According to Norwegian guidelines (38),
tertiary care centers are obliged to provide morbidly obese patients
with an appropriate treatment choice, either conservative or surgical.
Both treatment choices are publicly funded. Accordingly, we found it
unethical to assign patients to bariatric surgery if they both preferred
and qualified for a conservative lifestyle intervention program, and
vice versa. Other limitations include the lack of data illustrating the
patients’ adherence to the prescribed calorie restriction in both
groups, and physical activity in the LCD group, and the absence of a
weight maintenance period before the follow-up examination.
In summary, the findings from the present study indicate that a mod-
erate caloric restriction combined with aerobic physical exercise can
significantly reduce arterial stiffness in morbidly obese individuals
after only 7 weeks of intervention. A LCD proved to be less effec-
tive in reducing arterial stiffness and showed no significant effect in
spite of a clinically significant weight loss. It did, however, have a
beneficial effect on both glucose and lipid metabolism, highlighting
that important cardiovascular risk factors can be rapidly modified in
morbidly obese individuals through a LCD.O
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Effects of Intensive Lifestyle Intervention and Gastric Bypass
on Aortic Stiffness: A 1-Year Nonrandomized Clinical Study
Espen Gjevestad1,2, Jran Hjelmesæth1,3, Rune Sandbu1 and Njord Nordstrand1
Objective: To compare the long-term effects of Roux-en-Y gastric bypass (GBS) and intensive lifestyle
intervention (ILI) on aortic stiffness.
Methods: Nonrandomized clinical trial. Aortic stiffness was assessed by carotid-femoral pulse wave
velocity (cfPWV) using high-fidelity applanation tonometry.
Results: A total of 159 treatment seeking morbidly obese patients were included, 82 (54 females) in the
GBS-group and 77 (48 females) in the ILI-group. Participants in the GBS-group were younger (42.069.9
vs. 46.46 10.5 years), heavier (BMI 45.76 5.3 vs. 42.06 4.9 kg/m2), and had lower systolic pressure
(137619 vs. 1456 18 mm Hg) and pulse pressure (576 16 vs. 65617 mm Hg), all P0.006. Mean (SD)
cfPWV at baseline was 8.66 1.7 m/s in the GBS-group and 8.661.9 m/s in the ILI-group, P50.959. At
follow-up, mean (95%CI) weight loss was larger in the GBS-group 243.3(246.0 to 240.7) vs.
212.1(214.6 to 29.6)kg than in the ILI-group, P<0.001. The mean change in cfPWV was 20.02(20.31
to 0.27)m/s in the GBS-group and 0.03(20.28 to 0.33)m/s in the ILI-group, both P0.412; adjusted
between-group difference (ANCOVA) 0.05(20.40 to 0.49)m/s, P5 0.836. The adjusted regression analysis
showed that weight loss was associated with increased cfPWV in the GBS-group.
Conclusion: GBS and ILI had no significant long-term effects on aortic stiffness in treatment-seeking
morbidly obese individuals.
Obesity (2014) 00, 00-00. doi:10.1002/oby.20880
Introduction
Obesity is a global health concern of epidemic proportions (1) and is
associated with increased risk of diabetes, obstructive sleep apnea,
cardiovascular disease (CVD), some cancer types and premature death
(2). The cornerstone of obesity management is weight loss, and both
dietary and surgically induced weight loss improve the CVD risk pro-
file in terms of reduced blood pressure, blood glucose, and lipid lev-
els in morbidly obese individuals (3). In addition, increased aerobic
fitness and physical activity improve CVD risk independent of weight
loss, especially in unfit overweight and obese individuals (4). CVD
risk assessment in obese individuals is largely based on established
risk estimates such as the Framingham Risk Score which emphasizes
smoking habits, lipid levels, and blood pressure (5).
Aortic stiffness provides additional information regarding CVD risk
beyond traditional risk factors (6). Further, unlike fluctuating risk fac-
tors like blood lipids, glucose, and hypertension, aortic stiffness repre-
sents the accumulated damaging effects of all these measures over time
(7). Aortic stiffness is largely determined by structural changes in the
arterial wall such as (1) increased collagen-elastin ratio, (2) fractures of
elastic lamella and the cross-linking of collagen, and (3) increased
amount of advanced glycation end-products. Structural changes in aorta
occur slowly over a period of years (8) while other factors like adre-
nergic activity and aerobe exercise may modulate aortic compliance
over a short space of time (9,10). Aortic stiffness is considered a valid
surrogate end point of CVD (7) and is also an independent predictor of
all-cause mortality (7) and cardiovascular morbidity and mortality
(7,11,12). Carotid to femoral pulse wave velocity (cfPWV) has been
recommended as the gold-standard measure of aortic stiffness (13,14).
Some short-term (<12 months) studies have shown reduced aortic
stiffness after various lifestyle intervention programs in normal
weight (15), overweight (16), obese (17), and morbidly obese
patients (18). Similarly, some long-term (1-year) studies have
demonstrated beneficial effects of weight loss on aortic stiffness in
metabolically healthy obese patients after diet alone (19), diet and
physical activity (20), and diet or bariatric surgery (21). In addition,
one study demonstrated reduced cfPWV after weight loss in obese
diabetic patients (22). However, the comparative effect of bariatric
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surgery and intensive lifestyle intervention (ILI) on aortic stiffness
remains unknown.
The primary aim of this study was to compare the 1-year effect of
an ILI program and a surgical weight loss program on cfPWV in
morbidly obese individuals. Our main hypothesis was that patients
who underwent Roux-en-Y gastric bypass surgery (GBS) after an
initial low calorie diet would have a larger mean 1-year reduction of
cfPWV compared to those who underwent an ILI program.
Methods
Study design
This is the second part of a nonrandomized clinical trial comparing
the effects of an ILI and an initial 7-week low-calorie diet (LCD)
followed by GBS on aortic stiffness in treatment seeking morbidly
obese patients (Clinical Trials.gov Identifier NCT00626964). Prelim-
inary results from baseline (23), and short-term results after 7 weeks
(18) are published elsewhere. The protocol was approved by the
regional ethics committee of the Southern Norway Regional Health
Authority (identifier S-05175). All procedures were conducted
according to the principles expressed in the Declaration of Helsinki
(24). Written informed consent was provided by all participants.
Setting
The present study was conducted at the Morbid Obesity Center,
Vestfold Hospital Trust, from February 2008 to June 2012. Before
inclusion, patients were either assigned to an ILI program at the
Clinic of Physical Medicine and Rehabilitation (CPMR) or to an ini-
tial LCD followed by GBS at the Morbid Obesity Center (MOC).
Participants
All participants were recruited from our tertiary care center. For
practical reasons and to maximize compliance, participants had to
reside within 100 km of either the CPMR or MOC. The patients in
the ILI-group were all selected from patients that had registered for
participation in a standardized health promotion and weight reduc-
tion program at the CPMR. Participants in the GBS-group were
selected from patients as a result of undergoing bariatric surgery at
our hospital. The decision regarding the type of intervention to be
undertaken was made prior to inclusion to the present study and was
not part of the protocol.
Inclusion criteria were BMI 35 kg/m2 with at least one obesity-
related comorbidity, or a BMI 40 kg/m2. Patients were excluded if
they had uncompensated heart failure, cardiac arrhythmias, unstable
angina, end-stage renal disease, bleeding disturbances, serious psy-
chiatric disorders, serious eating disorders, cardiac pacemakers,
intra-cardiac devices, or a recent cerebrovascular event or myocar-
dial infarction (within the past 6 months).
Interventions
The first 7 weeks of ILI is described in detail elsewhere (18).
Briefly, the ILI included both a dietary and physical intervention.
The first year of the intervention was divided into two stages
(Figure 1). The first 12 weeks included treatment sessions 3 days
per week, with patients participating in two supervised training ses-
sions for 60-90 min and lectures on nutrition, physical activity, and
motivation each day. Patients received a dietary plan with an energy
restriction of 1000 kcal/day of the calculated total energy expendi-
ture at baseline (25). Study participants had individual sessions with
qualified personnel who used elements of a lifestyle modification
intervention in order to invoke behavioral change in the participants.
During weeks 13-52 patients received monthly follow-up, alternating
between group based and individual sessions every other month.
Patients were advised to maintain physical activity for 60-90 min
per day in order to increase or maintain weight loss (26), and during
the individual sessions patients were told to describe their physical
activity level.
Preceding surgery, patients in the GBS-group completed a 7 weeks
LCD (< 900 kcal per day; Figure 1). Laparoscopic Roux-en-Y GBS
were performed in 94 patients. The gastric pouch was about 25 ml,
Figure 1 Flow chart of interventions.
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while the intestinal limb lengths were measured as follows: alimen-
tary limb 120 cm, biliopancreatic limb 60 cm, and common channel,
variable length. A standardized regimen of dietary supplements and
a proton pump inhibitor were prescribed to all patients after surgery.
Outcomes
The main outcome variable was the 1-year change in aortic stiffness
measured by cfPWV. Secondary outcome variables were changes in
blood pressure, body weight, and body composition.
Data source and measurements
Detailed descriptions of data sources and measurements are published
elsewhere (18). Briefly, all participants underwent medical examina-
tions which included collection of blood samples, measurement of
body weight, height, and waist circumference, and analysis of body
composition using bioelectrical impedance analysis (Inbody 720,
Body Composition Analyzer, Biospace, Seol, South Korea). Resting
blood pressure was measured using an electronic blood pressure
recorder with an appropriately sized cuff (Dinamap
VR
, ProCare Series,
G.E. Medical Systems, Buckinghamshire, UK) with the patient sitting
in an upright position. Arterial hypertension was defined by either a
systolic blood pressure 140 mm Hg, diastolic blood
pressure 90 mm Hg or the use of antihypertensive medication.
Ischemic heart disease was defined as a history of stable coronary
artery disease, percutaneous coronary intervention, coronary artery
bypass graft surgery, or myocardial infarction. Mean arterial pressure
(MAP) was calculated as [(diastolic pressure x 2)1 systolic pressure]/
3 (27). Type 2 diabetes was diagnosed in patients who had a prior
history of type 2 diabetes or a fasting serum glucose level 7.0
mmol/L (28). Model Assessment Insulin Resistance (HOMA-IR) was
calculated as [fasting serum glucose (mmol/L) 3 fasting serum insu-
lin (pmol/L)]/135 (29) and low-density lipoprotein cholesterol (LDL)
concentrations were estimated using the Friedewald equation (30).
The SphygmoCor
VR
system (AtCor Medical, Sidney, Australia) and a
single high-fidelity applanation tonometer (Millar
VR
) were used to
measure cfPWV. Pulse waves were obtained sequentially from the
carotid and femoral artery. The travel distance was calculated by
subtracting the distance between the carotid artery and the sternal
notch from the distance between the sternal notch and the femoral
artery (13). The subtracted travel distance measured at baseline was
used in the calculations of cfPWV at follow-up.
Physical activity level was measured with a self reported questionnaire
(CONOR) (31) at 59 weeks follow-up. The questionnaire divides physical
activity into two main parts: leisure time physical activity and occupa-
tional physical activity. Physical activity during leisure time was further
divided into light physical activity (not sweaty and breathless) and vigor-
ous physical activity (sweaty and breathless), and scored according to
duration (hour/week) (none, <1, 1-2, >3). Occupational physical activity
was scored according to type of work (mainly sedentary, mainly walking,
mainly walking or/and carrying, heavy manual labor).
Laboratory analyses
Analyses of serum glucose and blood lipids were performed using
dry reagent slide technology on the Vitros FS 5.1 (Ortho-Clinical
Diagnostics, NY, USA). Glycated hemoglobin (HbA1c) was ana-
lyzed using high performance liquid chromatography on Tosoh
HLC-723 G7 (Tosoh Corporation, Tokyo, Japan). Sera for analysis
of insulin were stored at 220C and analyzed within one week of
blood sampling (Linco Research, St. Charles, MO).
Sample size
The sample size was calculated based on a publication demonstrating
a mean reduction of 1.4 m/s in cfPWV after 8% nonsurgical weight
loss (22). We anticipated a mean 1 year weight loss of 8% and 30%,
and a mean6SD reduction in cfPWV of 1.46 2.8 and 2.86 2.8 m/s,
in the lifestyle and surgery groups, respectively. To show a statisti-
cally significant difference between the two groups at a power of
80% (a5 0.05), at least 126 individuals (63 in each group) had to
complete the study. To allow for a drop-out rate of< 40% it was nec-
essary to include 200 patients (100 in each group).
Statistical methods
Data are presented as mean6 SD or number (%) unless otherwise
specified. Differences between groups at baseline were analyzed
using independent samples t-tests for continuous variables and Fish-
er’s exact tests for categorical variables. Within-group changes from
baseline to follow-up were analyzed using paired samples t-tests for
continuous data and McNemar’s test for categorical data. The
Figure 2 Flow chart.
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potential interaction between gender and treatment choice was ana-
lyzed using two-way analysis of covariance. The difference in
cfPWV between groups at 59-weeks follow-up were analyzed using
one-way analysis of covariance (ANCOVA) including age, gender,
history of coronary artery disease, baseline BMI, MAP, heart rate,
and cfPWV as covariates. Differences in systolic blood pressure, dia-
stolic blood pressure, and pulse pressure at follow-up were analyzed
using ANCOVA including age, gender, baseline BMI, history of
TABLE 1 Baseline characteristics, body composition, and cardiovascular risk factors among 159 morbidly obese patients who
completed the study according to treatment choice
Intensive lifestyle
intervention (n577)
Gastric bypass
surgery (n5 82) P-value
Age (years) 46.46 10.5 42.06 9.9 0.006
Gender, female (%) 48 (62) 54 (66) 0.741
Diabetes (%) 17 (22) 24 (29) 0.365
Hypertension (%) 59 (78) 50 (61) 0.026
Ischemic heart disease (%) 12 (16) 2 (2) 0.004
Smokers (%) 8 (10) 17 (21) 0.084
Weight and anthropometric measures
Weight (kg) 1246 20 1376 22 <0.001
Body mass index (kg/m2) 42.06 4.9 45.76 5.3 <0.001
Waist circumference (cm) 1266 12 1326 12 0.001
Fat mass (kg) 57.66 12.1 66.56 12.5 <0.001
Skeletal muscle mass (kg) 37.56 7.2 39.46 8.1 0.120
cfPWV and blood pressure
Pulse wave velocity (carotid femoral) (m/s) 8.66 1.9 8.66 1.7 0.959
Systolic blood pressure (mm Hg) 1456 18 1376 19 0.006
Diastolic blood pressure (mm Hg) 816 11 796 13 0.523
Pulse pressure (mm Hg) 656 17 576 16 0.002
Mean arterial pressure (mm Hg) 1026 11 996 14 0.074
Heart rate (beats/min) 796 13 776 14 0.288
Glucose and lipid metabolism
Insulin (pmol/L)† 87 (48, 115) 93 (58, 140) 0.144
Glucose (mmol/L)† 5.3 (4.9, 6.4) 5.4 (5.1 6.4) 0.248
HbA1c (%)† 5.7 (5.4, 6.1) 5.8 (5.3, 6.3) 0.772
HOMA-IR† 3.4 (1.9, 5.7) 4.1 (2.3, 6.2) 0.157
Total cholesterol (mmol/L) 5.16 1.0 4.96 1.0 0.287
LDL-cholesterol (mmol/L) 3.16 1.0 3.16 0.9 0.936
HDL-cholesterol (mmol/L)† 1.2 (1.0, 1.4) 1.1 (0.9, 1.3) 0.072
Triglycerides (mmol/L)† 1.4 (1.1, 2.1) 1.5 (1.0, 2.0) 0.820
Drugs
Statins (%) 18 (23) 12 (15) 0.223
Any antihypertensive drugs (%) 35 (46) 29 (35) 0.201
Beta blocker (%) 14 (18) 10 (12) 0.376
Calcium channel blocker (%) 12 (16) 12 (12) 0.647
Renin-angiotensin-aldosteron-system inhibitor (%) 28 (36) 23 (28) 0.309
Diuretics (%) 18 (23) 15 (18) 0.442
Other blood pressure medications (%) 6 (8) 4 (5) 0.525
Any antidiabetic/ glucose lowering drugs (%) 18 (23) 19 (23) 0.999
Glitazone (%) 2 (3) 5 (6) 0.444
Sulfonylurea (%) 5 (7) 8 (10) 0.567
Insulin (%) 4 (5) 1 (1) 0.999
Dipeptidyl peptidase-4 inhibitor (%) 0 1 (1) 0.999
Metformin (%) 12 (16) 16 (20) 0.540
Values reported are number (%) or mean6SD unless otherwise noted. Independent sample t-test was used for normally distributed data and Mann-Whitney for nonpara-
metric data. Fischer’s exact test was used for categorical data. †Reported as Median (Q1, Q3) as a result of skewed distribution.
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coronary artery disease, and baseline status in dependent variable as
covariates.
In addition, we performed post hoc subgroup correlation analyses
between changes in anthropometric variables and changes in cfPWV
in the two treatment groups. Finally, multiple linear regression anal-
yses with cfPWV-changes as effect variable and age, gender, history
of coronary artery disease, and baseline values of BMI, mean arte-
rial pressure, heart rate, cfPWV, and anthropometric parameters as
explanatory variables were performed in each treatment group.
P-values below 0.05 were considered statistically significant. Partic-
ular attention should, however, be directed towards smaller P-values,
i.e., those below 0.01, because a considerable number of P-values
have been calculated.
Results
A total of 239 individuals were eligible, 39 declined to participate,
leaving 200 (64% female) participants to be included in the study
(Figure 2). During the first 7 weeks, 13 individuals in the ILI-group
and seven individuals in the GBS-group withdrew. During the last
period of 52 weeks an additional 13 patients in the ILI-group and nine
patients in the GBS-group withdrew, while one patient re-entered the
ILI-group at 59 weeks follow-up. This leaves 159 (64% female) com-
pleters (80% of all included patients) in the present analysis, a total
number of 77 (76%) in the ILI-group and 82 (84%) in the GBS-group.
The GBS-patients were approximately 4 years younger, 13 kg heav-
ier, and had lower systolic blood pressure, pulse pressure, and a
lower prevalence of hypertension and ischemic heart disease com-
pared to the ILI-patients. The treatment groups did not differ signifi-
cantly in terms of cfPWV or in the use of anti-hypertensive drugs,
lipid-lowering drugs, and antidiabetic drugs (Table 1).
Changes in aortic stiffness, blood pressure and
heart rate
The average cfPWV for completers in both groups at baseline, 7 and
59 weeks are shown in Figure 3. As previously reported (18), in the
short-term (7-weeks) the ILI-group had a significantly larger mean
(95% CI) reduction of cfPWV than the GBS-group (low calorie
diet); 20.6 (20.8, 20.4) m/s vs. 20.2 (20.4, 0.0) m/s, adjusted
between-group difference 0.4 (0.1, 0.6) m/s, P5 0.004. In contrast,
there were no significant changes in cfPWV from baseline to 59-
weeks in either treatment group, and no significant adjusted between
group difference was found (Figure 3 and Table 2). No significant
interaction between gender and treatment group was found
(P5 0.158). Patients in the GBS-group had a significantly larger
decline in heart rate compared to patients in the ILI-group and
tended to have larger reductions of systolic and diastolic blood pres-
sure (Table 2).
Impact of weight loss according to treatment
group
Figure 4 illustrates that weight loss and reduced WC were associated
with decreasing cfPWV in the ILI-group, but, in contrast, with
increasing cfPWV in the GBS-group. After adjustments for age, gen-
der, history of coronary artery disease, and baseline values of BMI,
MAP, heart rate, and cfPWV, multiple linear regression analyses
showed that the associations between changes in cfPWV and changes
in WC, BMI, and body weight remained statistically significant in
the GBS-group only (all P< 0.006).
Weight loss, glucose metabolism, and lipids
Patients in the GBS-group had, compared to patients in the ILI-
group, a larger percentage weight loss, 32% vs. 10%, and greater
reductions of mean waist circumference, fat mass, and skeletal mus-
cle mass (Table 2).
Patients in the GBS-group also achieved larger reductions of serum
insulin, glucose, HbA1c, HOMA-IR, total cholesterol, LDL choles-
terol, and triglycerides, and a larger increase in mean HDL choles-
terol compared to patients in the ILI-group (Table 2).
Changes in medications
The proportion of patients treated with any antihypertensive and
antidiabetic drugs decreased significantly during the first 59 weeks
in the surgery group only. Specifically, the number of GBS-patients
treated with RAAS-inhibitors, beta blockers, and diuretics decreased
from 23 to 13 (44%), 10 to 4 (60%), and 15 to 7 (53%), respec-
tively, all P< 0.032. The number of patients using sulfonylurea or
metformin decreased from 8 to 0 (100%) and 16 to 3 (81%),
P5 0.008 and P< 0.001, respectively. There was no significant
change in the use of statins in either group, both P> 0.374.
Physical activity level at follow-up
The majority of patients reported that they completed >3 hours/
week of light physical activity and >3 hours/week of vigorous phys-
ical activity at follow-up, with no significant differences between
groups (Supporting Information Table 1).
Discussion
Our results did not confirm the hypothesis that patients undergoing
bariatric surgery would achieve a larger mean 1-year reduction of
Figure 3 Short- and long-term mean adjusted changes in aortic carotid femoral pulse
wave velocity (cfPWV) (m/s, 95%CI) in the morbidly obese patients who underwent
intensive lifestyle intervention (ILI) or Roux-en-Y gastric bypass surgery (GBS).
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cfPWV than controls completing an ILI-program. In addition, and to
some surprise, despite considerable 1-year weight losses in both
treatment groups (10% and 32%), the average cfPWV did not change
significantly within either group. To our knowledge, this is the first
study to compare the effect of bariatric surgery and an ILI-program
on cfPWV. Previous studies, including our own, have demonstrated
the beneficial short-term (7 weeks-6 months) effects of various life-
style intervention programs on cfPWV in normal weight (15), over-
weight (16), and obese populations (17,18). In contrast, our results
did not confirm the findings of some previous prospective long-term
(1 year) studies demonstrating significant reductions of aortic stiff-
ness after weight loss induced by diet alone (19), diet and physical
activity (20), diet or bariatric surgery (21), and diet with/without
orlistat (22). Rather, and to the contrary, the adjusted cfPWV
remained stable in both the GBS- and the ILI-group 1 year after
start of treatment.
The apparent discrepancy between previous studies and the present
one might have several explanations. First, in contrast with our
study of treatment seeking morbidly obese subjects, several previ-
ous studies (19-21) included obese but otherwise healthy popula-
tions. It is plausible that subjects with obesity related comorbid-
ities, like the majority of our patients, have a higher frequency of
structural changes associated with aortic stiffness in the aortic wall
than their metabolically healthy obese counterparts (9,10) and that
the potential reversal of such changes may take several years (8).
Further, one previous study included nontreatment seeking dia-
betic, but otherwise healthy obese individuals (22). Approximately
two-thirds of the participants achieved a decrease in cfPWV after 1
year, and individuals with the highest baseline values showed the
largest improvement. This finding might partly be explained by
regression to the mean, and the lack of adjustments for possible
confounding factors could partly explain the difference in results
compared to our own. Additionally, a significant number of partic-
ipants in the GBS-group stopped taking antihypertensive and anti-
diabetic drugs during the study. The former might partly explain
the modest decrease in blood pressure and, as cfPWV is partly
pressure dependent, the absence of beneficial changes in aortic
stiffness in the surgical group. In fact, antihypertensive drugs may
reduce aortic stiffness beyond their blood pressure lowering effects
(32). In addition, the use of metformin (33) and statins (34) have
been associated with reduced arterial stiffness. The discontinuation
of metformin might also have worked against any weight loss
induced decline in cfPWV.
TABLE 2 Within-group changes and adjusted between-group differences in carotid to femoral pulse wave velocity, blood
pressure, heart rate, anthropometric measures, glucose metabolism, and lipids in 159 morbidly obese patients during the
study
Intensive lifestyle
intervention group (n577)
Gastric bypass surgery
group (n5 82)
Adjusted difference
between groups P-value
Pulse wave velocity (carotid femoral) (m/s)
a 0.03 (20.28 to 0.33) 20.02 (20.31 to 0.27) 0.05 (20.40 to 0.49) 0.836
Systolic blood pressure (mm Hg)a 22 (26 to 3) 28 (213 to 24)* 6 (0 to 13) 0.057
Diastolic blood pressure (mm Hg)a 21 (23 to 2) 24 (26 to 22) 3 (0 to 7) 0.067
Pulse Pressure (mm Hg)a 0 (24 to 4) 25 (29 to 22)** 5 (0 to 10) 0.074
Mean Arterial Pressure (mm Hg)a 21 (24 to 2) 26 (28 to 23)* 4 (0 to 8) 0.038
Heart rate (beats/min)a 26 (28 to 23)** 211 (214 to 29)** 7 (3 to 10) <0.001
Weight, kg 212.1 (214.6 to 29.6)** 243.3 (246.0 to 240.7)** 27.6 (24.0 to 31.1) <0.001
BMI, kg/m2 24.0 (24.9 to 23.2)** 214.4 (215.3 to 213.6)** 9.3 (8.2 to 10.5) <0.001
Waist circumference, cm 210.9 (213.2 to 28.6)** 230.5 (232.9 to 228.0)** 17.1 (13.6 to 20.5) <0.001
Fat mass, kg 210.2 (212.5 to 27.9)** 236.6 (238.9 to 234.3)** 24.2 (20.9 to 27.5) <0.001
Skeletal muscle mass, kg 20.5 (21.5 to 0.6) 24.1 (25.2 to 23.1)** 3.3 (1.7 to 4.9) <0.001
Glucose metabolism
Insulin, pmol/L 221 (234 to 28)* 281 (2102 to 259)** 41 (28 to 55) <0.001
Glucose, mmol/L 20.4 (20.8 to 0.1) 21.2 (21.6 to 20.8)** 0.7 (0.3 to 1.1) 0.002
HbA1C, % 20.4 (20.6 to 20.2)** 20.8 (21.0 to 20.5)** 0.3 (0.1 to 0.4) 0.001
HOMA-IR 21.0 (21.7 to 20.3)* 24.4 (25.8 to 23.0)** 2.0 (1.2 to 2.7) <0.001
Lipids
Total cholesterol, mmol/L 20.1 (20.2 to 0.1) 20.6 (20.8 to 20.4)** 0.6 (0.3 to 0.8) <0.001
LDL cholesterol, mmol/L 0.0 (20.2 to 0.2) 20.7 (20.8 to 20.5)** 0.7 (0.5 to 0.9) <0.001
HDL cholesterol, mmol/L 0.1 (0.1 to 0.2)** 0.3 (0.3 to 0.4)** 0.2 (0.1 to 0.3) <0.001
Triglycerides, mmol/L 20.3 (20.5 to 20.2)** 20.7 (20.8 to 20.5)** 0.3 (0.2 to 0.5) <0.001
*P< 0.05 **P< 0.001.
aAdjusted within-group values. Mean (95% CI). Within-group changes of the various outcome variables (left column) were analyzed with paired-samples t-test. Analyses of
covariance (ANCOVA) including age, gender, history of coronary artery disease, baseline BMI, MAP, heart rate, and baseline status in dependent variable as covariates for
cfPWV, age, gender, history of coronary artery disease baseline BMI, and baseline status in dependent variable as covariates for systolic blood pressure, diastolic blood
pressure and pulse pressure. Age, gender, and baseline status in dependent variable was included as covariates in ANCOVA analysis of heart rate, anthropometric meas-
ures, glucose metabolism, and lipids.
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Importantly, aortic stiffness is influenced by both functional and
structural factors (9,10,35,36). The results from the present analysis
demonstrate that the short-term reduction of cfPWV observed after 7
weeks of ILI (18) was a temporary one, and thus likely to be medi-
ated by changes in functional factors like increased physical fitness,
decreased heart rate and blood pressure and decreased activity in the
sympathetic nervous system (9,10). The findings that the greatest
reductions in heart rate and blood pressure as well as cfPWV
throughout the study period were observed in the ILI-group after 7
weeks of follow-up also support this. Accordingly, the small long-
term reductions in blood pressure and heart rate might partly explain
the lack of association between treatment choice and changes in
cfPWV as shown in the present study.
Post hoc subgroup analyses did not reveal any significant association
between weight loss and changes in cfPWV after lifestyle interven-
tion, which is in accordance with the negative findings from the
SAVE trial (37). The apparent detrimental effect of surgically
induced weight loss on arterial stiffness was somewhat surprising
and difficult to explain. Importantly, given the well known limita-
tions of post hoc subgroup analyses, this finding should be inter-
preted with caution (38). One might, however, speculate that a
Figure 4 Scatter plots of the relationship between changes in the explanatory variables body weight, BMI and waist circumfer-
ence, and changes in the effect variable cfPWV within each treatment group.
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massive weight loss may lead to a reflex increase in arterial resist-
ance as the hyporesponsive baroreflex caused by obesity related
chronic vasodilatation is abolished (39).
It is unlikely that our results are biased by measurement error since
all measurements were conducted at one center by two trained oper-
ators (EG and NN), both of whom were present at all measurements.
Our findings are further strengthened by the relatively large sample
size, long follow-up time and a considerable weight loss following
both interventions. In addition, all of the physical exercise sessions
in ILI were supervised by qualified personnel.
The major limitation of the study is the nonrandomized design.
Since both treatments are publicly funded and patients are supposed
to take an active role in a decision over treatment choice (40), we
found it ethically most appropriate to perform a nonrandomized
comparative study. Other minor limitations include the lack of data
describing patients’ adherence to the prescribed interventions (diet
and physical activity) and the use of self-reported use of medications
and level of physical activity. In addition, the use of sequential
measurements at the carotid and femoral sites might have affected
the reliability of the cfPWV measurements. However, to minimize
this potential bias cfPWV was measured three times at each mea-
surement point, and the averages of these measurements were used
in the calculations. Finally, we cannot exclude the possibility of a
false negative result (type 2-error), but a post-hoc power analysis
based on the number of participants completing the study demon-
strated a power of more than 80% to detect a clinically meaningful
between group difference in cfPWV change of 0.6 m/s (a5 0.05).
Perspective
Aortic stiffness measured by cfPWV is not only a measure of age-
related aortic stiffening (10), but also a potential risk factor for car-
diovascular disease (7). The findings of the present study suggest
that long-term aortic stiffness in morbidly obese individuals is not
significantly influenced by weight loss following bariatric surgery or
an intensive lifestyle program. Our findings need further verification
in future studies.O
Acknowledgments
EG and NN conducted all measurements. EG, JH, and NN analyzed
data. All authors were involved in writing the paper and had final
approval of the submitted and published versions. We thank the
patients who took part in this study. Further, we thank the following
employees at the Morbid Obesity Center at Vestfold Hospital Trust:
Dr.med Erling Saltvedt, Heidi Omre Fon, Berit Mossing Bjrka˚s,
and Linda Mathisen for their assistance with sampling and logistics,
PhD. Harald Weedon-Fekjær, Institute of Basic Medical Sciences at
University of Oslo, for statistical support, and Matthew McGee for
proofreading the manuscript.
VC 2014 The Obesity Society
References
1. Finucane MM, Stevens GA, Cowan MJ, et al. National, regional, and global trends
in body-mass index since 1980: Systematic analysis of health examination surveys
and epidemiological studies with 960 country-years and 9.1 million participants.
Lancet 2011;377:557-567.
2. Must A, Spadano J, Coakley EH, Field AE, Colditz G,Dietz WH. The disease
burden associated with overweight and obesity. JAMA 1999;282:1523-1529.
3. Rider OJ, Francis JM, Ali MK, et al. Beneficial cardiovascular effects of bariatric
surgical and dietary weight loss in obesity. J Am Coll Cardiol 2009;54:718-726.
4. McAuley PA, Blair SN. Obesity paradoxes. J Sports Sci 2011;29:773-782.
5. Anderson KM, Wilson PW, Odell PM, Kannel WB. An updated coronary risk
profile. A statement for health professionals. Circulation 1991;83:356-362.
6. Ben-Shlomo Y, Spears M, Boustred C, et al. Aortic pulse wave velocity
improves cardiovascular event prediction: An individual participant meta-
analysis of prospective observational data from 17,635 subjects. J Am Coll
Cardiol 2014;63:636-646.
7. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events
and all-cause mortality with arterial stiffness: A systematic review and meta-
analysis. J Am Coll Cardiol 2010;55:1318-1327.
8. Safar ME, Laurent S, Pannier BM, London GM. Structural and functional
modifications of peripheral large arteries in hypertensive patients. J Clin Hypertens
1987;3:360-367.
9. Tanaka H, Safar ME. Influence of lifestyle modification on arterial stiffness and
wave reflections. Am J Hypertens 2005;18:137-144.
10. Lakatta EG. Arterial and cardiac aging: Major shareholders in cardiovascular
disease enterprises: Part III: Cellular and molecular clues to heart and arterial aging.
Circulation 2003;107:490-497.
11. Laurent S, Boutouyrie P, Asmar R, et al. Aortic stiffness is an independent
predictor of all-cause and cardiovascular mortality in hypertensive patients.
Hypertension 2001;37:1236-1241.
12. Willum-Hansen T, Staessen JA, Torp-Pedersen C, et al. Prognostic value of aortic
pulse wave velocity as index of arterial stiffness in the general population.
Circulation 2006;113:664-670.
13. Laurent S, Cockcroft J, Van Bortel L, et al. Expert consensus document on arterial
stiffness: Methodological issues and clinical applications. Eur Heart J 2006;27:
2588-2605.
14. Mansia G, De Backer G, Dominiczak A, et al. 2007 ESH-ESC Guidelines for the
management of arterial hypertension: The task force for the management of arterial
hypertension of the European Society of Hypertension (ESH) and of the European
Society of Cardiology (ESC). Blood Press 2007;16:135-232.
15. Yoshizawa M, Maeda S, Miyaki A, et al. Effect of 12 weeks of moderate-intensity
resistance training on arterial stiffness: A randomised controlled trial in women
aged 32-59 years. Br J Sports Med 2009;43:615-618.
16. Guimaraes GV, Ciolac EG, Carvalho VO, D’Avila VM, Bortolotto LA, Bocchi EA.
Effects of continuous vs. interval exercise training on blood pressure and arterial
stiffness in treated hypertension. Hypertens Res 2010;33:627-632.
17. Dengo AL, Dennis EA, Orr JS, et al. Arterial destiffening with weight loss in
overweight and obese middle-aged and older adults. Hypertension 2010;55:855-
861.
18. Nordstrand N, Gjevestad E, Hertel JK, et al. Arterial stiffness, lifestyle intervention
and a low-calorie diet in morbidly obese patients-A nonrandomized clinical trial.
Obesity (Silver Spring, Md) 2013;21:690-697.
19. Wycherley TP, Brinkworth GD, Keogh JB, Noakes M, Buckley JD, Clifton PM.
Long-term effects of weight loss with a very low carbohydrate and low fat diet on
vascular function in overweight and obese patients. J Intern Med 2010;267:452-
461.
20. Cooper JN, Buchanich JM, Youk A, et al. Reductions in arterial stiffness with
weight loss in overweight and obese young adults: Potential mechanisms.
Atherosclerosis 2012;223:485-490.
21. Rider OJ, Tayal U, Francis JM, et al. The effect of obesity and weight loss on
aortic pulse wave velocity as assessed by magnetic resonance imaging. Obesity
(Silver Spring, Md) 2010;18: 2311-2316.
22. Barinas-Mitchell E, Kuller LH, Sutton-Tyrrell K, et al. Effect of weight loss and
nutritional intervention on arterial stiffness in type 2 diabetes. Diabetes Care 2006;
29:2218-2222.
23. Nordstrand N, Gjevestad E, Dinh KN, et al. The relationship between various
measures of obesity and arterial stiffness in morbidly obese patients. BMC
Cardiovasc Disord 2011;11:7.
24. World Medical Association declaration of Helsinki. Recommendations guiding
physicians in biomedical research involving human subjects. JAMA 1997;277:925-
926.
25. Schofield WN. Predicting basal metabolic rate, new standards and review of
previous work. Hum Nutr Clin Nutr 1985;39(Suppl 1):5-41.
26. Wing RR, Hill JO. Successful weight loss maintenance. Annu Rev Nutr 2001;21:
323-341.
27. Wildman RP, Mackey RH, Bostom A, Thompson T, Sutton-Tyrrell K. Measures of
obesity are associated with vascular stiffness in young and older adults.
Hypertension 2003;42:468-473.
28. Diagnosis and classification of diabetes mellitus. Diabetes Care 2008;31(Suppl 1):
S55-S60.
29. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC.
Homeostasis model assessment: Insulin resistance and beta-cell function from
fasting plasma glucose and insulin concentrations in man. Diabtologia 1985;28:412-
419.
Obesity PWV, Bariatric Surgery and Lifestyle Gjevestad et al.
8 Obesity | VOLUME 00 | NUMBER 00 | MONTH 2014 www.obesityjournal.org
30. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-
density lipoprotein cholesterol in plasma, without use of the preparative
ultracentrifuge. Clin Chem 1972;18:499-502.
31. Naess O, Sogaard AJ, Arnesen E, et al. Cohort profile: Cohort of Norway
(CONOR). Int J Epidemiol 2008;37:481-485.
32. Seidlerova J, Filipovsky J, Mayer O, Wohlfahrt P, Cifkova R. Positive effects of
antihypertensive treatment on aortic stiffness in the general population. Hypertens
Res 2014;37:64-68.
33. Agarwal N, Rice SP, Bolusani H, et al. Metformin reduces arterial stiffness and
improves endothelial function in young women with polycystic ovary syndrome: A
randomized, placebo-controlled, crossover trial. J Clin Endocrinol Metab 2010;95:
722-730.
34. Rizos EC, Agouridis AP, Elisaf MS. The effect of statin therapy on arterial stiffness
by measuring pulse wave velocity: A systematic review. Curr Vasc Pharmacol
2010;8:638-644.
35. Hirsch J, Leibel RL, Mackintosh R, Aguirre A. Heart rate variability as a measure
of autonomic function during weight change in humans. Am J Physiol 1991;261:
R1418-R1423.
36. Arone LJ, Mackintosh R, Rosenbaum M, Leibel RL, Hirsch J. Autonomic nervous
system activity in weight gain and weight loss. Am J Physiol 1995;269:R222-R225.
37. Hughes TM, Althouse AD, Niemczyk NA, Hawkins MS, Kuipers AL, Sutton-
Tyrrell K. Effects of weight loss and insulin reduction on arterial stiffness in the
SAVE trial. Cardiovasc Diabetol 2012;11:114.
38. Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine–
reporting of subgroup analyses in clinical trials. N Engl J Med 2007;357:2189-2194.
39. Emdin M, Gastaldelli A, Muscelli E, et al. Hyperinsulinemia and autonomic
nervous system dysfunction in obesity: Effects of weight loss. Circulation 2001;
103:513-519.
40. Jakobsen GS, Hofso D, Roislien J, Sandbu R, Hjelmesaeth J. Morbidly obese
patients–who undergoes bariatric surgery? Obes Surg 2010;20:1142-1148.
Original Article Obesity
CLINICAL TRIALS: BEHAVIOR, PHARMACOTHERAPY, DEVICES, SURGERY
www.obesityjournal.org Obesity | VOLUME 00 | NUMBER 00 | MONTH 2014 9
Supp Table 1 Self-reported physical activity at 59 weeks follow up in morbidly obese patients which 
completed the interventions. 
  Intensive lifestyle 
intervention 
(n=60) 
Gastric bypass 
surgery 
(n=54) 
P-value 
Light physical activity Nothing 0 (0) 0 (0) 0.880 
≤1 hour/week 1 (2) 1 (2) 
1-2 hours/week 7 (12) 8 (15) 
≥3 hours/week 52 (87) 45 (83) 
Vigorous physical 
activity 
Nothing 2 (3) 6 (11) 0.267 
≤1 hour/week 5 (8) 7 (13) 
1-2 hours/week 21 (34) 17 (32) 
≥3 hours/week 34 (55) 24 (44) 
Work Sedentary work 23 (39) 19 (36) 0.485 
Walking 24 (41) 19 (36) 
Walking and carrying 11 (19) 11 (21) 
Heavy manual labor 1 (2) 4 (8) 
Number (%), between group differences analyzed using Chi-Square test. The response rate of self reported physical activity 
level was 78% in the ILI-group and 66% in the GBS group. 
 
